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ABSTRACT 
Precision oncology tests that profile tumors to identify clinically 
actionable targets have rapidly entered clinical practice. Effective 
visual presentation of the results of these tests is crucial in 
accurate clinical decision-making. In current practice, these 
results are typically delivered to oncologists as static prints, who 
then incorporate them into their clinical decision-making process. 
However, due to a lack of guidelines for standardization, different 
vendors use different report formats. There is very little known on 
the effectiveness of these report formats or the criteria necessary 
to improve them. In this study, we have aimed to identify both the 
tasks and the needs of oncologists from precision oncology report 
design and then to improve the designs based on these findings. 
To this end, we report results from multiple interviews and a 
survey study (n=32) conducted with practicing oncologists. Based 
on these results, we compiled a set of design criteria for precision 
oncology reports and developed a prototype report design using 
these criteria, along with feedback from oncologists. 
Keywords: Visual design, visual communication, precision 
medicine, oncology. 
1 INTRODUCTION 
Recent advances in next-generation sequencing (NGS) 
technologies [1] are improving our understanding of the role of 
inter-individual variability in the genomic lesions that drive 
disease predisposition or progression. Coupled with their low cost, 
genomic information from these technologies is increasingly 
being utilized in the clinic [2]. In fact, past several years have 
witnessed an emerging shift towards precision medicine 
approaches, which refer to treatments that are precisely tailored 
for each individual patient based on his or her unique genomic or 
epigenomic characteristics and lifestyle [3]–[5].  Since the 
mutational landscape of tumor cells plays an important role in the 
diagnosis, prognosis and treatment of multiple cancers, precision 
medicine approaches are especially well-suited for oncology 
practice. Under the remit of the Clinical Laboratory Improvement 
Amendments (CLIA) of 1988, genetic tests that are deemed to be 
analytically valid (e.g. accuracy and precision of gene mutation 
detection) by Centers for Medicare and Medicaid Services (CMS) 
can be adopted without any review of data regarding their clinical 
utility [6], and the utilization of test results to guide therapy 
resides entirely within the discretion of the treating physician. 
Consequently, gene panels that typically involve the targeted 
sequencing of 25 to 400 known cancer related genes are offered 
by both commercial vendors such as Caris (Figure 1—
www.carislifesciences.com), Foundation Medicine 
(www.foundationmedicine.com), GeneDx (www.genedx.com) 
[7], [8] and medical centers. Among the commercial vendors, the 
most frequently used panel is that from FoundationOne (Figure 1), 
which has produced more than 22,000 somatic tests in 2014 [9].  
Results obtained from gene panel tests are typically delivered to 
clinicians as static print reports. So far there are no established 
standards, specifications or FDA guidelines. However, we can 
categorize the content commonly found in today’s existing vendor 
reports into 5 main sections: patient/test identification, genetic 
alterations (mutations), therapeutic implications, test-related 
information, and appendix containing references and disclaimers 
(Table 1). Some vendor reports also provide one or more of the 
following: prognostic information, toxicity information, and 
pathologist interpretation of results. However, these are not 
necessarily included across different vendor reports. Since 
somatic genetic alterations form the basis of these tests, details 
provided on specific mutations drive most of the technical 
information presented in the reports.  
The contents of the gene panel tests are critical as they alter 
treatment decisions in the clinic (i. e. hormone receptor targeting 
of hormone receptor positive breast tumors). However, challenges 
remain in communicating and interpreting these results. Several 
studies that investigate and report physicians’ attitudes toward 
genetic testing and related concerns in the clinical care and 
practice of oncology suggest issues related with interpretation. In 
one of the earliest studies [10], only 29% of physicians reported 
that they felt qualified to provide genetic counselling to their 
patients, and nearly 75% of physicians thought that clear 
guidelines are not available for managing patients with positive 
test results. Similarly, more than 89% of physicians reported a 
need for guidelines. In a more recent study, Miller et al [11] 
conducted structured interviews with 17 physicians about 
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Figure 1: First page of sample reports from Foundation Medicine 
(left); Caris (right). See Supplementary Figure S1 and S2 
respectively for full sample reports. 
 
genomic testing in oncology, and the results indicated a need for 
decision guidelines and education to assist physicians.  
In a larger study, Gray et al. [12] surveyed 160 clinically active 
oncologists at an academic cancer center to assess their current 
use of somatic testing, and their genomic confidence: 22% 
reported low confidence in their genomic knowledge. This study 
underscored a need for both evidence-based guidelines and 
enhanced genomics education efforts for physicians. In fact, 
genomic confidence was one of the strongest predictors of 
physicians’ attitudes about and anticipated use of genetic testing. 
As is the case for the content, there are also no standards for the 
design and presentation of information in precision oncology 
reports. The layout, organization, design and representation of 
information at all levels vary widely across different vendors. In 
some instances, the results may indicate mutations in a large 
number of genes across multiple pathways, generating massive 
amounts of information [13]. For busy practicing oncologists, 
handling and interpreting such detailed and vast volumes of 
information presented in a nonstandard and impractical manner 
becomes a significant challenge. Thus, employing practical and 
effective reports is a crucial factor in the clinical adoption and 
utilization of precision oncology tests by oncologists. 
To our knowledge, there are arguably no vendor-neutral/non-
commercial research efforts aimed to improve and evaluate the 
effectiveness of precision oncology reports. On the other hand, 
multiple studies have focused on radiology reports. In [14], 
clinicians were asked to rank a variety of hypothetical radiology 
reports in order of preference. Reports presented in tables as 
opposed to traditional prose format were preferred and clinicians 
also preferred more detailed reports that included a clinical 
comment by the radiologist, for both normal and abnormal results. 
In a similar study [15], referring clinicians and radiologists 
indicated that structured reports provided better content and 
greater clarity than reports in simple text. In a study [16] that 
involved general practitioners (GP) who were asked to rank 
preferences for ultrasound reports with differing formats and 
levels of detail, the results again clearly suggested that GPs 
preferred detailed reports in a tabulated format. 
Here, we investigated the challenges oncologists face in 
interpreting precision oncology reports and provided visualization 
solutions to some of these issues in a two-stage process, where we 
first identified design issues and requirements and then developed 
a design prototype. At every step of this process, we solicited 
feedback from the target audience, practicing oncologists.  
2 DESIGN ISSUES AND EXPECTATIONS 
In the first phase of our study, we aimed to understand the current 
status, needs and expectations of oncologists in terms of precision 
oncology report usage in their clinical practice.  For this purpose, 
we conducted informal interviews with several oncologists at 
Mount Sinai Health System (New York, USA) regarding their 
current experience, and expectations from the design of precision 
oncology reports. Based on these initial round of feedbacks, we 
prepared a draft survey questionnaire to get input from a wider 
community of oncologists. We revised the draft survey based on 
feedback from the same group to improve the relevance of the 
survey questions to the tasks of oncologists. After several rounds 
of revisions, we finalized the survey questionnaire. 
2.1 Survey and Participants 
We conducted the survey at a Hematology/Medical Oncology 
Grand Rounds meeting at Mount Sinai Health System in April 
2016. After discussing the goals and scope of the project, the 
survey questionnaire was provided to all oncologists present at the 
meeting to fill voluntarily.  The complete survey questionnaire 
can be found in Supplementary Table 1. In total, 32 oncologists 
responded to the survey. 
Table 2 summarizes the demographics of the survey 
participants. The participants were almost exclusively made up of 
medical oncologists, majority of which were male (71%). Post-
medical school years of experience exhibited a wide-range and 
were almost evenly distributed. The most commonly listed 
clinical foci among participating oncologists were blood cancer 
(42%), hematology (23%), and breast cancer (19%), where 31% 
of oncologists declared themselves to have multiple clinical foci. 
Table 2. Demographics of Oncologist Survey (N = 32) 
Demography Respondents 
Gender (n = 31) 
Male 
Female 
22 
9 
Years since medical school (n = 32) 
0 - 5 
6 - 10 
11 - 15 
16 - 20 
21 - 25 
26 - 30 
31 - 35 
36 - 40 
5 
8 
2 
2 
3 
4 
4 
4 
Type of Physician (multiple answers 
allowed) 
(n = 31) 
Surgical Oncologist 
Medical Oncologist 
Radiation Oncologist 
1 
31 
0 
Table 1. Contents of a Typical Precision Oncology Report 
Main Section Sub-Sections Details 
Patient/Test 
Identification 
- Patient Information 
- Specimen Information 
- Physician/Pathologist Information 
- name, gender, id, etc. 
- specimen site, type, collection date, etc. 
- name, contact information, etc. 
Genetic Alterations 
(Mutations) 
- Detected gene alterations 
- Not detected gene alterations 
- gene, type of mutation, interpretation 
- disease-relevant gene  
Therapeutic 
Implications 
- FDA Approved Therapies in patient’s tumor type 
- FDA Approved Therapies in different tumor type 
- Clinical Trials 
- drug name, interpretation 
- drug name, interpretation 
- title, phase, location, id, etc. 
Test-related Information - Gene List 
- Methodology 
- list of all genes assayed in the test 
- specific technologies and procedures used to 
generate the test results 
Appendix - References 
- Disclaimers 
- scientific works referred throughout the report  
- FDA status, legal/technical liabilities, etc. 
 2.2 Results 
Here, we provide a summary of our survey results. A complete 
analysis can be found in Supplementary Figure S3. 
Genetic alterations are the most important information. 
Oncologists who participated in the survey stated that the most 
important information they look for in a tumor profiling report is 
genetic alterations (84%, Figure S3.4.). Therapy information and 
clinical trial information were also selected by 69% and 66% 
respectively (multiple selections were allowed). 
Finding actionable genetic alterations is the most time-consuming 
task. By a wide margin, the most time-consuming component of 
interpreting such a report was stated as finding actionable genetic 
alteration information (57%, Figure S3.5) followed by clinical 
trials information (29%) and information about therapies (21%). 
Verbosity and clutter limit the effectiveness of the reports. In 
general, oncologists stated that they preferred more concise 
reports; and that the most troublesome aspect of reading these 
reports was the verbosity of technical information (59%, Figure 
S3.6). Ease of locating actionable summary (45%) and ease of 
locating critical information (34%) were also identified as issues, 
which to a certain degree supports our previous observation. 
Layout and visual encoding are the most critical elements of a 
vendor report. By a wide margin, oncologists selected the layout 
and presentation of information (61%, Figure S3.7) as the most 
problematic feature of a vendor report that makes it harder to 
interpret its content (next: more technical details, 32%), 
emphasizing the importance of our overall study. Furthermore, 
none of the participants stated that they were satisfied with current 
reports (Figure S3.8) when asked regarding the effectiveness of 
the reports.  Furthermore, 58% of oncologists suggested 
standardizing the design of vendor reports. Finally, 50% 
suggested adding visualizations to summarize various data and to 
improve the effectiveness of oncology reports. Even though the 
percentage of those suggesting visual summarization of data may 
not look substantially high, it is quite noteworthy to observe such 
a demand from a diverse demography of clinicians who are highly 
accustomed to dealing with extensive textual information.  
3 REPORT DESIGN 
Based on our findings from the survey study, and additional more 
in-depth feedback from interviews with several oncologists, we 
identified six main criteria for precision oncology report design, 
as listed in Table 3. 
3.1 Design Process 
Conforming to the design goals in Table 3, we designed several 
report prototypes in an iterative process. Briefly, we used different 
visual encoding and styling (e.g. shapes, colors, scaling, etc.) 
options to present information in a concise and clear format. In 
addition, we utilized multiple design elements (e.g. bold/larger 
font, shading, etc.) to highlight important information. 
Furthermore, we employed contrasting design elements (e.g. 
varying colors and shapes, etc.) to arrange the large-volume of 
information in an easily distinguishable manner. At each iteration, 
we had in-depth consultations with two oncologists and revised 
the designs accordingly. Among multiple prototypes that came out 
of this process, the one with the highest consensus is shown in 
Figure 2. Accordingly, the rest of the discussions regarding the 
report prototype (RP) refer to this specific design. 
3.2 Design Choices 
The main choices we made in the RP are summarized as follows. 
First, due to the conventional usage and expectations of clinicians 
(DG-4), the test/patient identification information was kept at the 
top of the page. We then designed a Results Summary section at 
the top left-half of the page to address DG-3. In this section, we 
used a table format and incorporated basic visual elements (DG-6) 
to summarize the information. To address DG-1, we designed a 
Genomic Alterations section at the top right-half of the page. This 
Table 3. Design Goals for Precision Oncology Reports 
Design Goal Explanation 
DG-1: Present Genetic alteration (Biomarker) 
information in the best possible way 
This is the most important information for oncologists (Fig. S3.4), and also the 
most time-consuming component during interpretation (Fig. S3.5). Thus, relevant 
information should be presented in a concise, non-confusing manner. Also, the 
whole component (especially the actionable items) should be made prominent in 
the overall layout of the report. 
DG-2: Distinguish clinically-relevant 
information from non-relevant technical 
information 
 
Verbosity of technical information is the most troublesome aspect of reading these 
reports (Fig. S3.6). Oncologists expressed that they end up sifting through a lot of 
data to access information that is clinically important. Thus, the overall layout 
should keep essential (clinically relevant) information together before non-essential 
(e.g. standard disclaimers, technology-related explanation, etc.) information. 
DG-3: Actionable summary results should be 
easily discoverable 
Ease of locating actionable summary and critical information is among the most 
troublesome aspects of reports (Fig. S3.6). Actionable summary result information 
should be kept together, centralized, and emphasized with design elements. 
DG-4: Presentation of information should be 
natural and easy-to-follow for oncologists 
Organization and presentation of technical information should be in accordance 
with the customs and experiences of oncologists. Also, design elements used with 
an aim to help structure/organize information should not interfere with the 
interpretation activities of oncologists. 
DG-5: As much as possible, the design should be 
consistent/compatible with existing vendor 
reports 
Unless there is good reasoning not to do so, commonly used and well-performing 
design aspects of existing vendor reports can be reused. This, to a certain degree, 
helps with the desired standardization expectations (Fig. S3.8) of oncologists. 
DG-6: When applicable, employ proper visual 
summary/representation of data 
To address the verbosity aspect of technical information in existing reports (Fig. 
S3.6) and oncologists’ expectations of summarized data (Fig. S3.8), proper visual 
design elements should be incorporated. Utilization of these visual elements should 
not be in contradiction with the objectives of previous design goals. 
section lists all the detected genetic alterations as well as disease-
relevant alterations that were not detected. Associated therapy 
options are also displayed using the same visual elements, to help 
keep the consistency of notation and information across different 
sections (DG-4). Therapeutic Implications follow next, taking the 
whole page width, because of the type and amount of information 
it embeds. This section closely resembles the same section in the 
design of FoundationOne reports (DG-5), with the addition of 
color-encoded display of each row depending on whether the 
genomic alteration is clinically actionable. Finally, overall layout 
and organization of information displayed in this first page of RP 
follows from DG-2. 
4 DISCUSSION AND CONCLUSION 
In this study, we introduced a set of design guidelines for 
improving the effectiveness of precision oncology reports. To 
derive these guidelines, we conducted both one-on-one interviews 
and a systemic survey with clinical oncologists. We present here a 
new oncology report design informed by the derived guidelines.  
How effective is our new report design? Our future work will 
assess the comparative merits and limitations of our design with 
respect to frequently used reports through a quantitative user 
study. Currently, like many medical reports, oncology reports are 
generated for clinicians. Another avenue of future research is to 
improve the effectiveness of these reports for patients, enabling 
their more informed involvement in the decision making process. 
Furthermore, while oncology reports are invariably viewed as 
static presentations in current clinical practice, we expect their 
evolution into interactive mediums. Therefore, future 
investigations on the effective design of interactive visual reports 
are warranted.  In the meantime, our work here provides insights 
and visual improvements for the increased effectiveness of static 
reports as a reference for future studies.  
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Therapy
8 Genomic alterations
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Notes:
Therapy: Alteration: Alteration:
Patient Information
Date of Birth
Gender
Medical Record #
Specimen ID
1/1/1991 
Male 
Not Given S12- 
38877 20
Physician Information
Client
Ordering Physician
Additional Recipient
Pathologist
Mount Sinai 
Dr. Cancer 
N/A 
N/A
Test Information
Specimen Received
Specimen Site
Date of Collection
Specimen Type
05/06/2013 
Soft Tissue 
09/26/2012 
Slide
Figure 2: Our oncology report design informed by the design 
guidelines.  
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Date of Birth Medical Facility 
Sex Male Ordering Physician Specimen Received 
FMI Case # Additional Recipient Specimen Site Lymph Node 
Medical Record # Medical Facility ID # Date of Collection 
Specimen ID Pathologist Specimen Type 
ABOUT THE TEST: 
FoundationOne™ is a next-generation sequencing (NGS) based assay that identifies genomic alterations within hundreds of cancer-related genes. 
PATIENT RESULTS TUMOR TYPE: LUNG ADENOCARCINOMA 
11 genomic findings Genomic Alterations Identified†
ERBB2 amplification – equivocal⧺ 
10 therapies associated with potential clinical benefit 
0 therapies associated with lack of response 
19 clinical trials 
NF2 E427* 
STK11 splice site 921-1G>C 
CDKN1B E105fs*14 
FOXP1 E490* 
KDM5C W983* 
LRP1B loss exons 6-14 
SPTA1 Q1346fs*3, splice site 3570-2A>T 
TP53 I255S 
Additional Findings†
Tumor Mutation Burden TMB-High; 37.53 Muts/Mb 
Additional Disease-relevant Genes with No 
Reportable Alterations Identified†
EGFR 
KRAS 
ALK 
BRAF 
MET 
RET 
ROS1 
THERAPEUTIC IMPLICATIONS 
† For a complete list of the genes assayed and performance specifications, 
please refer to the Appendix 
⧺ See Appendix for details SA
MP
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FDA-Approved Therapies 
(in patient’s tumor type) 
FDA-Approved Therapies 
(in another tumor type) Potential Clinical Trials
ERBB2 
amplification - equivocal 
Afatinib Ado-trastuzumab emtansine 
Lapatinib 
Pertuzumab 
Trastuzumab 
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section 
Tumor Mutation Burden 
TMB-High; 37.53 Muts/Mb 
Nivolumab 
Pembrolizumab 
Atezolizumab Yes, see clinical trials 
section 
NF2 
E427* 
None Everolimus 
Temsirolimus 
Yes, see clinical trials 
section 
STK11 
splice site 921-1G>C 
None Everolimus 
Temsirolimus 
Yes, see clinical trials 
section 
CDKN1B 
E105fs*14 
None None None 
FOXP1 
E490* 
None None None 
KDM5C 
W983* 
None None None 
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GENOMIC ALTERATIONS 
GENE 
ALTERATION 
ERBB2 
amplification - 
equivocal 
INTERPRETATION 
Gene and Alteration: ERBB2 (also known as HER2) encodes a receptor tyrosine kinase which is in the 
same family as EGFR. Amplification or overexpression of ERBB2 can lead to excessive proliferation and 
tumor formation1. 
Frequency and Prognosis: In the TCGA datasets, ERBB2 amplification or mutation was observed in 6% 
of lung adenocarcinoma cases2. HER2 overexpression has been documented in 11-32% of non-small cell 
lung cancers (NSCLC), and is higher in lung adenocarcinomas (38%) than in squamous cell (16%) and 
large cell (17.9%) tumors3,4. A tendency toward shorter survival has been observed in patients with 
NSCLC harboring ERBB2 amplification and strong HER2 protein expression5. 
Potential Treatment Strategies: Based on extensive clinical evidence, ERBB2 amplification or activating 
mutation may predict sensitivity to therapies targeting HER2, including antibodies such as 
trastuzumab6,7,8,9,10,11, pertuzumab in combination with trastuzumab8,12,13, and ado-trastuzumab 
emtansine (T-DM1)14, as well as dual EGFR/HER2 kinase inhibitors such as lapatinib15,16,17,18, 
afatinib11,19,20,21,22, neratinib23,24, and dacomitinib25. In patients with breast cancer, concurrent PIK3CA or 
PTEN alterations that activate the PI3K pathway have been associated with resistance to therapies that 
target HER2, including trastuzumab and lapatinib26,27,28,29,30. However, other studies have reported 
conflicting results, with one study suggesting that neither PIK3CA nor PTEN alteration is associated with 
trastuzumab resistance31, and another study reporting a correlation between PIK3CA mutation and 
increased clinical response to the combination of letrozole and lapatinib32. Clinical trials of agents aimed 
at preventing or overcoming resistance to anti-HER2 therapies are under way, including agents targeting 
the PI3K-AKT pathway or HSP9033,34. 
Tumor Mutation 
Burden 
TMB-High; 37.53 
Muts/Mb 
Gene and Alteration: Tumor mutation burden (TMB, also known as mutation load) is a measure of the 
number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a 
tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as 
ultraviolet light in melanoma35,36 and cigarette smoke in lung cancer37,38, mutations in the proofreading 
domains of DNA polymerases encoded by the POLE and POLD1 genes39,40,41,42,43, and microsatellite 
instability (MSI)39,42,43. The tumor seen here harbors a high TMB. This type of mutation load has been 
shown to be associated with sensitivity to immune checkpoint inhibitors, including anti-CTLA-4 therapy 
in melanoma44, anti-PD-L1 therapy in urothelial carcinoma45, and anti-PD-1 therapy in non-small cell 
lung cancer and colorectal cancer38,46, potentially due to expression of immune-reactive neoantigens in 
these tumors38. 
Frequency and Prognosis: High TMB has been reported in 8-13% of non-small cell lung carcinomas 
(NSCLCs), including 8.2-9.6% of adenocarcinomas and 8.5% of squamous cell carcinomas (SCCs) (Spigel 
et al., 2016; ASCO Abstract 9017, Jiang et al., 2016; ASCO Abstract e23128). High-TMB NSCLC rarely 
harbors known driver mutations (1% each with EGFR, ALK, ROS1, or MET), with the exception of BRAF 
(10.3%) or KRAS (9.4%) mutation (Spigel et al., 2016; ASCO Abstract 9017). Higher mutational load was 
reported to be associated with later stage NSCLC in a study of 48 African-American patients (Schwartz 
et al., 2016; ASCO Abstract 8533). Although some studies have reported a lack of association between 
smoking and mutational burden in NSCLC (Schwartz et al., 2016; ASCO Abstract 8533)47,48, several other 
large studies did find a strong association with increased TMB49,50,51,52. A large study of Chinese patients 
with lung adenocarcinoma reported a shorter median overall survival (OS) for tumors with a 
higher number of mutations in a limited gene set compared with lower mutation number (48.4 vs. 61.0 
months)47. 
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Potential Treatment Strategies: On the basis of emerging clinical evidence, increased TMB may be 
associated with greater sensitivity to immunotherapeutic agents, including anti-CTLA-444, anti-PD-L145, 
and anti-PD-1 therapies38,46; FDA-approved agents include ipilimumab, atezolizumab, pembrolizumab, 
and nivolumab. In multiple solid tumor types, higher mutational burden has corresponded with 
response and improved prognosis. Pembrolizumab improved progression-free survival (14.5 vs. 3.4-3.7 
months) in patients with non-small cell lung cancer (NSCLC) and higher mutational load (greater than 
200 nonsynonymous mutations; hazard ratio = 0.19)38. In studies of patients with either NSCLC or 
colorectal cancer (CRC), patients whose tumors harbor elevated mutational burden reported higher 
overall response rates to pembrolizumab38,46. Anti-PD-1 therapies have achieved clinical benefit for 
certain patients with high mutational burden, including 3 patients with endometrial adenocarcinoma 
who reported sustained partial responses following treatment with pembrolizumab53 or nivolumab54 
and two patients with biallelic mismatch repair deficiency (bMMRD)-associated ultrahypermutant 
glioblastoma who experienced clinically and radiologically significant responses to nivolumab55. In 
patients with melanoma, mutational load was associated with long-term clinical benefit from 
ipilimumab44,56 and anti-PD-1 treatment (Johnson et al., 2016; ASCO Abstract 105). For patients with 
metastatic urothelial carcinoma, those who responded to atezolizumab treatment had a significantly 
increased mutational load [12.4 mutations (mut) per megabase (Mb)] compared to nonresponders (6.4 
mut/Mb)45. 
NF2 
E427* 
Gene and Alteration: Merlin, encoded by NF2, coordinates cell contact with growth signals; the 
inactivation of Merlin disrupts this mechanism and can lead to unrestrained growth despite cell 
contact57. NF2 alterations that disrupt the FERM domain (amino acids 22-311), including in-frame 
deletions that disrupt the Paxillin-binding region (aa 50-70) of the FERM domain58, and/or the C- 
terminal region (amino acids 506-547), such as observed here, are predicted to be 
inactivating58,59,60,61,62,63,64. Heterozygous germline NF2 loss or inactivation is associated with 
neurofibromatosis type 2 syndrome, which results in the development of vestibular schwannomas, 
meningiomas, ependymomas, and ocular disturbances65,66,67. Prevalence for this disorder in the general 
population is estimated to be 1:25,00067. In the appropriate clinical context, germline testing of NF2 is 
recommended. 
Frequency and Prognosis: NF2 mutation or homozygous loss is not common in lung non-small cell lung 
cancer (NSCLC) and has been reported in ~1% of squamous cell carcinoma and adenocarcinoma 
samples analyzed in the TCGA datasets2,68. In one study, NF2 mutation has been reported in just 1/45 
lung cancer cases69. 
Potential Treatment Strategies: On the basis of strong clinical evidence from multiple case 
reports70,71,72,73 as well as extensive preclinical evidence74,75, NF2 inactivation may predict sensitivity to 
mTOR inhibitors, including approved agents everolimus and temsirolimus. Loss or inactivation of NF2 
may also predict sensitivity to FAK inhibitors, based on clinical data in mesothelioma (Soria et al., 2012; 
ENA Abstract 610) and strong preclinical data76,77. Limited preclinical and clinical evidence in vestibular 
schwannoma suggests possible sensitivity of NF2-deficient tumors to the pan-ERBB inhibitor 
lapatinib78,79. Similarly, on the basis of limited clinical (Subbiah et al., 2011; ASCO Abstract 2100) and 
preclinical80,81,82 evidence, NF2 inactivation may predict sensitivity to MEK inhibitors, such as approved 
agents trametinib and cobimetinib. These and other relevant compounds are being investigated in 
clinical trials. A Phase 1b trial of a combination of the mTOR inhibitor everolimus and the MEK inhibitor 
trametinib in patients with solid tumors reported frequent adverse events and was unable to identify a 
recommended Phase 2 dose and schedule for the combination83. 
S
MP
LE
Patient Name Report Date Tumor Type 
Lung adenocarcinoma 
For more comprehensive information please log on to the Interactive Cancer Explorer™ 
To set up your Interactive Cancer Explorer account, contact your sales representative or call 1-888-988-3639. 
Electronically Signed by Jeffrey S. Ross, M.D. | Jeffrey S. Ross, M.D., Medical Director | CLIA Number: 22D2027531 | 10 August 2016 
Foundation Medicine, Inc., 150 2nd Street, 1st Floor, Cambridge, MA 02141 | 1-888-988-3639 page 5 of 38 
GENE 
ALTERATION 
STK11 
splice site 921-1G>C 
INTERPRETATION 
Gene and Alteration: The serine/threonine kinase STK11 (also called LKB1) activates AMPK and 
negatively regulates the mTOR pathway in response to changes in cellular energy levels84. LKB1 acts as 
a tumor suppressor in cancer, as loss of function promotes proliferation and tumorigenesis85,86. 
Functional disruption of the STK11 kinase domain (amino acids 49-309) or STRAD binding domain 
(amino acids 320-343) through mutation or loss, as observed here, is predicted to be 
inactivating87,88,89,90,91,92,93,94,95,96,97. Germline mutations in STK11 underlie Peutz-Jeghers syndrome (PJS), a 
rare autosomal dominant disorder associated with a predisposition for tumor formation98. This disorder 
has an estimated frequency between 1:29,000 and 1:120,000, although reported rates in the literature 
vary greatly. Although gastrointestinal tumors are the most common malignancies associated with PJS, 
patients also exhibit an 18-fold increased risk of developing other epithelial cancers98,99,100, and 
individuals with this syndrome have a 30-50% risk of developing breast cancer98,100. Given the 
association with PJS, in the appropriate clinical context testing for the presence of germline mutations in 
STK11 is recommended. 
Frequency and Prognosis: Several clinical studies have found STK11 mutation to be common in non- 
small cell lung cancer (NSCLC) (15-35%), with alterations more prevalent in lung adenocarcinomas (13- 
34%) than in lung squamous cell carcinoma (2-19%)51,68,101,102,103,104,105. STK11 mutations in NSCLC often 
co-occur with activating KRAS mutations104,105. In transgenic mouse models, animals expressing mutant 
KRAS developed lung adenocarcinomas, whereas the KRAS-mutant/LKB1-deficient mice developed an 
expanded histological spectrum of tumors that included large cell and squamous cell carcinomas102. 
Decreased expression of LKB1 correlates with poor prognosis and/or higher histological grade in 
patients with some cancer types, although prognosis in patients with NSCLC is not known106,107. 
Potential Treatment Strategies: Increased mTOR signaling is present in LKB1-deficient tumors, 
suggesting therapies targeting mTOR may be relevant for tumors with STK11 alterations84,102,108,109,110. 
The mTOR inhibitors everolimus and temsirolimus are FDA approved for the treatment of other tumor 
types, and are being investigated in clinical trials for several indications111,112,113,114. A PJS patient with 
pancreatic cancer and an STK11 mutation experienced a partial response to the mTOR inhibitor 
everolimus115. Loss of STK11 also leads to activation of the downstream kinase SRC, suggesting that 
inhibitors such as dasatinib or bosutinib may be relevant for the treatment of LKB1-deficient tumors85. 
CDKN1B 
E105fs*14 
Gene and Alteration: CDKN1B encodes the cyclin-dependent kinase inhibitor p27, which controls cell 
cycle progression through G1 phase by binding to prevent action of cyclin E/CDK2 and cyclin D/CDK4 
protein complexes. Removal of this inhibition is required for cellular transition from quiescence to a 
proliferative state. There is some evidence that germline variants in CDKN1B are associated with 
increased risk for several tumor types, including prostate116, endometrial117, and colorectal cancers118. 
Frequency and Prognosis: Somatic inactivating mutations in CDKN1B have been documented in fewer 
than 1% of tumors (COSMIC, 2016). A survey of 350 breast cancers found somatic mutations in 
CDKN1B in approximately 1% of cases119. Mutations in p27 have been associated with multiple 
endocrine neoplasia syndrome, and truncating alterations have been shown to disrupt normal 
subcellular localization of p27 due to the loss of a nuclear localization motif120,121. Loss of p27 expression 
has been described in some studies as a negative indicator of prognosis in patients with B-cell 
lymphomas, but the relationship between p27 levels and cell proliferation is somewhat controversial122. 
Changes in the levels of p27 have been observed in the context of multiple myeloma, and decreased 
levels of p27 are associated with reduced overall survival and more aggressive cancers123,124,125. A 
preclinical study showed that p27 is essential for cell cycle arrest of T-cell acute lymphoblastic leukemia 
(T-ALL) cells by glucocorticoid treatment126. 
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Potential Treatment Strategies: There are no targeted therapies available to address genomic 
alterations in CDKN1B. 
FOXP1 
E490* 
Gene and Alteration: FOXP1 encodes the protein 'forkhead box protein P1', a transcription factor 
previously reported as a tumor suppressor, but one which can also function as an oncogene when 
shorter isoforms are expressed127,128. 
Frequency and Prognosis: Loss of FOXP1 expression has been reported to be a frequent event in 
endometrial cancer129. FOXP1 translocations have been described in acute lymphoblastic 
leukemia130,131, and deletions of the chromosomal region where FOXP1 is located have been reported in 
acute myeloid leukemia and myeloproliferative neoplasms132,133. Genomic rearrangements that disrupt 
the 5' regulatory region of FOXP1 have been detected and characterized in several lymphomas134,135,136. 
Such alterations have been demonstrated to result in expression of N-terminally truncated variants of 
FOXP1, or aberrant expression of full length FOXP1 driven by strong regulatory elements, such as IGH, as 
observed in the t(3;14)(p13;q32) translocation137. In a genome-wide association study, polymorphisms 
at the FOXP1 locus were found to be significantly associated with Barrett esophagus and esophageal 
adenocarcinoma138. Conflicting data have been presented on the prognostic impact of FOXP1 expression, 
as high expression of FOXP1 is associated with poor prognosis in patients with cutaneous large B-cell 
lymphomas or mucosal tissue-associated lymphoid tissue (MALT) lymphomas, but improved prognosis in 
patients with breast or lung cancer134,135,139,140,141. 
Potential Treatment Strategies: There are no approved therapies available to address alterations in 
FOXP1. 
KDM5C 
W983* 
Gene and Alteration: KDM5C encodes a histone lysine demethylase that acts, along with related 
histone-modifying enzymes, to control gene expression in response to developmental and 
environmental cues142. In addition to its role as a histone-modifying demethylase, KDM5C has been 
suggested to play a role in regulation of the SMAD3 signal transduction response to TGF-beta, a role that 
would be consistent with function as a tumor suppressor143. Germline inactivating mutations in KDM5C 
cause an X-linked intellectual disability syndrome also characterized by short stature and 
hyperreflexia144. 
Frequency and Prognosis: Somatic mutations of KDM5C have been observed in a number of solid 
tumors and the role of KDM5C inactivation has been well characterized in clear cell renal cell 
carcinoma (ccRCC)145,146,147,148. However, KDM5C amplification and overexpression has been implicated 
in prostate cancer where KDM5C has been associated with poor prognosis149. 
Potential Treatment Strategies: There are no targeted therapies available to address genomic 
alterations in KDM5C. SA
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loss exons 6-14 
INTERPRETATION 
Gene and Alteration: LRP1B encodes the low-density lipoprotein receptor-related protein 1B, also 
called LRPDIT. LRP1B is subject to frequent mutation, deletion, and/or silencing in cancers, leading to 
the hypothesis that it behaves as a tumor suppressor. However, the mechanism of tumor suppression 
is unclear50,150,151. The LRP1B protein consists of three regions: an extracellular LDL-receptor (amino 
acids 25-4444), a transmembrane region (4445-4467), and a smaller cytoplasmic portion (4468-4599). 
Somatic mutations that lead to C-terminal truncation of LRP1B are common, and in vitro studies suggest 
that an intracellular domain fragment released by a gamma-secretase-like activity translocates to the 
nucleus where it suppresses anchorage-independent cell growth152. In addition, heterozygous mice that 
express a C-terminally truncated LRP1B missing codons 3547- 4599, which includes the transmembrane 
and cytoplasmic domain were reported to be viable, with no phenotype; however, mice homozygous for 
the mutation or the null mutation were inviable153. Therefore, it is possible that truncated proteins are 
still functional. 
Frequency and Prognosis: LRP1B mutations have been frequently reported in many types of cancer, 
including 12-16% of multiple myeloma154,155, 6% of diffuse large B-cell lymphoma, 3% of chronic 
lymphocytic leukemia/small cell lymphoma, 1% of acute myeloid leukemia, and 7% (2/29) of chronic 
myeloid leukemia cases (COSMIC, 2016). In addition, LRP1B mutations have been frequently reported in 
many solid tumors: 32% of melanoma, 30-39% of squamous cell lung cancer, 28-32% of lung 
adenocarcinoma, 26% of stomach cancer, and 6-20% of head and neck squamous cell carcinoma, bladder 
cancer, and colorectal cancer cases (cBioPortal, 2016). LRP1B is commonly inactivated in non- small cell 
lung cancer cell lines, and low expression of LRP1B mRNA was associated with poor patient 
outcome156,157,158. 
Potential Treatment Strategies: There are no therapies or clinical trials that address the loss or 
mutation of LRP1B in cancer. In some tumor types, such as high-grade serous cancer (HGSC), LRP1B 
deletion has been reported to be associated with resistance to liposomal doxorubicin159. 
SPTA1 
Q1346fs*3, splice 
site 3570-2A>T 
Gene and Alteration: SPTA1 encodes the protein spectrin alpha chain 1, a component of the 
cytoskeleton of erythrocytes160. Germline mutations in SPTA1 have been associated with disorders 
featuring abnormally shaped erythrocytes, such as elliptocytosis and spherocytosis161. 
Frequency and Prognosis: SPTA1 mutations have been found in 9% of glioblastoma samples analyzed 
in one study162, and mutations have been reported with high prevalence in melanoma, lung tumors, and 
esophageal tumors (COSMIC, cBioPortal, 2016). 
Potential Treatment Strategies: There are no therapies available to directly address genomic 
alterations in SPTA1 in cancer. 
TP53 
I255S 
Gene and Alteration: Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, 
is common in aggressive advanced cancers163. Mutations affecting the DNA binding domain (aa 100- 
292), the tetramerization domain (aa 325-356), or the C-terminal regulatory domain (aa 356-393), such 
as observed here, are thought to disrupt the transactivation of p53-dependent genes and are predicted 
to promote tumorigenesis164,165,166,167. Germline mutations in TP53 are associated with the very rare 
disorder Li-Fraumeni syndrome and the early onset of many cancers168,169,170,171,172,173. Estimates for the 
prevalence of germline TP53 mutations in the general population range from 1:5,000174 to 1:20,000173, 
and in the appropriate clinical context, germline testing of TP53 is recommended. S
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Frequency and Prognosis: TP53 is one of the most commonly mutated genes in lung cancer, and 
mutations in this gene have been reported in 43-80% of non-small cell lung cancers 
(NSCLCs)2,175,176,177,178 and specifically in 45% of lung adenocarcinoma samples179,180. Mutations in TP53 
have been associated with lymph node metastasis in patients with lung adenocarcinoma181. 
Potential Treatment Strategies: There are no approved therapies to address TP53 mutation or loss. 
However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor 
AZD1775182,183,184,185, therapies that reactivate mutant p53 such as APR-246186, or p53 gene therapy and 
immunotherapeutics such as SGT-53187,188,189,190 and ALT-801 (Hajdenberg et al., 2012; ASCO Abstract 
e15010). Combination of AZD1775 with paclitaxel and carboplatin achieved significantly longer 
progression-free survival than paclitaxel and carboplatin alone in patients with TP53-mutant ovarian 
cancer (Oza et al., 2015; ASCO Abstract 5506). Furthermore, AZD1775 in combination with carboplatin 
achieved a 27% (6/22) response rate and 41% (9/22) stable disease rate in patients with TP53-mutant 
ovarian cancer refractory or resistant to carboplatin plus paclitaxel (Leijen et al., 2015; ASCO Abstract 
2507). In a Phase 1 clinical trial, 8 of 11 evaluable patients receiving SGT-53 as a single agent exhibited 
stable disease191. Clinical trials of SGT-53 in combination with chemotherapy are underway. Additionally, 
the combination of a CHK1 inhibitor and irinotecan reportedly reduced tumor growth and prolonged 
survival in a TP53 mutant, but not TP53 wild-type, breast cancer xenotransplant mouse model192. Kevetrin 
has also been reported to activate p53 in preclinical studies and might be relevant in the 
context of mutant p53 (Kumar et al., 2012; AACR Abstract 2874). Clinical trials of these agents are under 
way for some tumor types for patients with a TP53 mutation. 
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THERAPIES 
FDA-APPROVED THERAPIES IN PATIENT TUMOR TYPE 
THERAPY SUMMARY OF DATA IN PATIENT TUMOR TYPE 
Afatinib Approved Indications: Afatinib is an irreversible kinase inhibitor that targets the kinase domains of 
EGFR, ERBB2/HER2, and ERBB4. It is FDA approved for the treatment of metastatic non-small cell lung 
cancer (NSCLC) in patients with EGFR exon 19 deletions or exon 21 (L858R) missense mutations. 
Gene Association: ERBB2 amplification or activating mutations may indicate sensitivity to afatinib on 
the basis of clinical evidence in various solid tumors11,19,193. 
Supporting Data: Phase 3 clinical trials have demonstrated that treatment with afatinib, compared to 
chemotherapy, leads to significantly increased progression-free survival for patients with EGFR- 
mutant NSCLC194,195, and increased overall survival (OS) for patients with EGFR exon 19 alterations 
specifically196. A Phase 3 trial comparing afatinib with erlotinib as second-line therapies for advanced 
lung squamous cell carcinoma reported significantly higher OS (7.9 months vs. 6.8 months) and disease 
control rate (DCR) (51% vs. 40%) for patients treated with afatinib197. Phase 2/3 studies of afatinib 
treatment for patients with erlotinib- or gefitinib-resistant NSCLC have generally reported partial 
responses (PRs) of only 7-9%22,198,199,200,201,202, and DCRs of more than 50%22; in particular, disease 
control was achieved for 2/2 patients with EGFR-amplified NSCLC22 and 9/14 patients with T790M- 
positive NSCLC202. The T790M mutation has been implicated in reduced response to afatinib201,203,204, 
with a secondary T790M mutation reported in 48% (20/42) of patients with afatinib-resistant lung 
adenocarcinoma203. The combination of afatinib with cetuximab resulted in a higher response rate 
(29%) for patients with erlotinib- or gefitinib-resistant disease205, including T790M-positive cases205,206, 
although adverse reactions may be a concern with this combination207. Upon progression on afatinib, 
further benefit has been reported from combination treatment with afatinib and paclitaxel208. 
Nivolumab Approved Indications: Nivolumab is a monoclonal antibody that binds to the PD-1 receptor and 
blocks its interaction with PD-L1 and PD-L2, thereby reducing inhibition of the antitumor immune 
response. It is FDA approved to treat unresectable or metastatic melanoma as both a single agent and 
in combination with the immunotherapy ipilimumab. Nivolumab is also approved to treat non- small 
cell lung cancer (NSCLC) following disease progression on prior treatments, advanced renal cell 
carcinoma following antiangiogenic therapy, and classical Hodgkin lymphoma (cHL) that has relapsed 
or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post- 
transplantation brentuximab vedotin. 
Gene Association: On the basis of emerging clinical data in patients with non-small cell lung cancer 
(Spigel et al., 2016; ASCO Abstract 9017)38, colorectal cancer46, or melanoma (Johnson et al., 2016; 
ASCO Abstract 105) and case reports in endometrial cancer53,54 and glioblastoma55, high tumor 
mutation burden (TMB) may predict sensitivity to anti-PD-1 therapies such as nivolumab. SA
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Supporting Data: Studies investigating the use of nivolumab as first-line treatment for patients with 
non-small cell lung carcinoma (NSCLC) reported an objective response rate (ORR) of 23% (12/53), 
median overall survival (OS) of 19.4 months, and 1-year OS rate of 73% with monotherapy209; 
combinations with platinum-based doublet chemotherapy (gemcitabine/cisplatin, 
pemetrexed/cisplatin, and paclitaxel/carboplatin) resulted in ORRs of 33-47%, 1-year OS rates of 50- 
87%, and 2-year OS rates of 25-62%210. In patients with platinum-refractory non-squamous NSCLC, 
nivolumab improved median OS (12.2 vs. 9.4 months) and the ORR (19% vs. 12%) compared with 
docetaxel; PD-L1 expression was associated with benefit from nivolumab in this study (OS hazard ratios 
of 0.40-0.59)211. In patients with previously treated squamous NSCLC, nivolumab resulted in longer 
median OS (9.2 vs. 6.0 months) and higher ORR (20% vs. 9%) than docetaxel, and PD-L1 expression was 
neither prognostic nor predictive of nivolumab efficacy212,213. Real-world studies of nivolumab for the 
treatment of NSCLC reported clinical benefit for 35-36% of patients (Crino et al., 2016; ASCO Abstract 
3067, Corny et al., 2016; ASCO Abstract e20633). A Phase 1 study of nivolumab (3 mg/kg) plus 
ipilimumab (1 mg/kg, every 6 or 12 weeks) as first-line treatment for advanced NSCLC resulted in ORRs 
of 31-39% and median PFS of 8.0-8.3 months (Hellmann et al., 2016; ASCO Abstract 3001). Nivolumab in 
combination with erlotinib for the treatment of chemotherapy-naive EGFR-mutant NSCLC achieved an 
ORR of 19%; additionally, 15% (3/20) partial responses (PR) and 45% (9/20) stable diseases were 
reported in cases with acquired erlotinib resistance (Rizvi et al., 2014; ASCO Abstract 8022). Nivolumab 
has shown intracranial activity, with disease control in the brain for 33% of patients (Goldman et al., 
2016; ASCO Abstract 9038)214. A small study of 3 patients with resectable NSCLC reported 1 complete 
response and 1 PR with nivolumab as neoadjuvant therapy (Forde et al., 2016; ASCO Abstract e20005). 
Pembrolizumab Approved Indications: Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and 
blocks its interaction with the ligands PD-L1 and PD-L2 to enhance antitumor immune responses. It is 
FDA approved to treat unresectable or metastatic melanoma and PD-L1-positive metastatic non- small 
cell lung cancer (NSCLC) refractory to prior therapy. 
Gene Association: On the basis of emerging clinical data in patients with non-small cell lung cancer 
(Spigel et al., 2016; ASCO Abstract 9017)38, colorectal cancer46, or melanoma (Johnson et al., 2016; 
ASCO Abstract 105) and case reports in endometrial cancer53,54 and glioblastoma55, high tumor 
mutation burden (TMB) may predict sensitivity to anti-PD-1 therapies such as pembrolizumab. 
Supporting Data: In a Phase 2/3 study for previously treated NSCLC with PD-L1 expression (on at least 
1% of tumor cells), pembrolizumab extended median overall survival (OS) (10.4-12.7 vs 8.2 months) 
when compared with docetaxel215. A Phase 1 study of pembrolizumab in NSCLC reported an overall 
response rate (ORR) of 19%, and median OS of 10.6 months and 22.1 months for previously treated 
and treatment-naive patients, respectively (Hui et al., 2016; ASCO Abstract 9026, Garon et al., 
2016; ASCO Abstract 9024)216. In both studies, pembrolizumab demonstrated greater efficacy in 
patients with PD-L1 expression on at least 50% of tumor cells, with ORRs (29-45%)215,216, median OS 
(14.9-17.3 months)215, and progression-free survival (PFS; 5.0-6.3 months)215,216 being increased for 
these patient populations. In a Phase 2 study of pembrolizumab for advanced PD-L1-positive NSCLC 
with brain metastases, 33% (6/18) of patients experienced brain metastases responses217. As first-line 
therapy for patients with EGFR/ALK wild-type advanced NSCLC, pembrolizumab plus platinum doublet 
chemotherapy (carboplatin/paclitaxel, carboplatin/paclitaxel/bevacizumab, or 
carboplatin/pemetrexed) achieved ORRs of 52% (13/25) and 59% (29/49) for patients with any 
histology or with nonsquamous NSCLC, respectively (Gadgeel et al., 2016; ASCO Abstract 9016). 
Pembrolizumab combined with the anti-CTLA4 antibody ipilimumab for patients with recurrent 
advanced NSCLC and at least one previous treatment reported an ORR of 24%, stable disease rate of 
40% (18/45), and median OS of 17 months (Gubens et al., 2016; ASCO Abstract 9027). A Phase 1 study 
of pembrolizumab in combination with the anti-4-1BB antibody utomilumab reported a partial 
response for 1 out of 6 cases with NSCLC (Tolcher et al., 2016; ASCO Abstract 3002). 
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ADDITIONAL THERAPIES – FDA-APPROVED IN OTHER TUMOR TYPES 
THERAPY SUMMARY OF DATA IN OTHER TUMOR TYPE 
Ado-trastuzumab 
emtansine 
Approved Indications: Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that 
targets the protein ERBB2/HER2 on the cell surface, inhibiting HER2 signaling218,219; it also releases 
the cytotoxic therapy DM1 into cells, leading to cell death219,220. T-DM1 is FDA approved for the 
treatment of HER2-positive (HER2+) metastatic breast cancer. 
Gene Association: ERBB2 activating mutations or amplification may predict sensitivity to T-DM1. 
Supporting Data: A patient with non-small cell lung cancer, disease progression on two prior lines of 
chemotherapy, and an activating ERBB2 alteration (exon 20 insertion) experienced a rapid and 
durable response to T-DM1221,222. The vast majority of data on the therapeutic use of T-DM1 has been 
collected in the context of breast cancer, although clinical trials investigating T-DM1 are underway in 
several tumor types, primarily in HER2+ cancers. A Phase 3 trial in 602 patients with HER2+ breast 
cancer reported that those who received T-DM1 showed an improved progression-free survival (PFS) 
and a lower rate of adverse events than patients who received the physician’s choice of therapy223. A 
second Phase 3 trial in 991 patients with HER2+ breast cancer reported that T-DM1 brought about 
significantly longer overall survival (OS) and PFS, as compared with lapatinib plus capecitabine, in 
patients previously treated with trastuzumab plus a taxane14,224. Two separate Phase 2 trials reported 
robust activity for single-agent T-DM1 as a treatment for HER2+ metastatic breast cancer in patients 
previously treated with standard HER2-directed therapies or HER2-directed therapies plus 
chemotherapy, with objective response rates of 34.5% and 25.9%, respectively, and PFS of 6.9 months 
and 4.9 months, respectively225,226. 
Lapatinib Approved Indications: Lapatinib is a tyrosine kinase inhibitor that targets EGFR, ERBB2/HER2, and to 
a lesser degree, ERBB4. It is FDA approved in combination with capecitabine or letrozole for the 
treatment of HER2-overexpressing (HER2+) metastatic breast cancer. 
Gene Association: Activation or amplification of ERBB2 may predict sensitivity to lapatinib. In one 
study, a patient with inflammatory breast cancer and ERBB2 V777L and S310F activating mutations, 
but without ERBB2 amplification or protein overexpression, experienced tumor shrinkage in 
response to combined treatment with lapatinib and trastuzumab18. 
Supporting Data: Investigations into the efficacy of lapatinib have primarily been in the context of 
breast cancer. In preclinical assays, lapatinib reduced cell proliferation in vitro and reduced the 
number and size of tumors in mouse xenograft models of EGFR- and ERBB2-amplified non-small cell 
lung cancer (NSCLC) cells227. A Phase 1 study of single-agent lapatinib included 9 unselected patients 
with lung cancer and reported 1 case of prolonged stable disease228. In a Phase 2 trial in patients with 
advanced or metastatic NSCLC, lapatinib monotherapy did not result in significant tumor reduction, but 
further investigation of lapatinib in combination with other therapies may be warranted229. 
Pertuzumab Approved Indications: Pertuzumab is a monoclonal antibody that interferes with the interaction 
between HER2 and ERBB3. It is FDA approved in combination with trastuzumab and docetaxel to 
treat a subset of patients with HER2-positive (HER2+) breast cancer12. 
Gene Association: ERBB2 amplification or activating mutations may predict sensitivity to 
pertuzumab. SA
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Supporting Data: In a Phase 1 study of pertuzumab in advanced cancer, 2/19 patients reported partial 
responses and 6/19 patients reported stable disease after two cycles, including one patient with lung 
cancer230. In another Phase 1 study in Japanese patients with solid tumors, no responses were 
observed and stable disease was reported in 1 of 7 patients with NSCLC231. In a Phase 2 study of 
pertuzumab in NSCLC, no responses were observed and the progression-free survival was 6.1 weeks232. 
Phase 1 and 2 trials of pertuzumab in combination with erlotinib in NSCLC have reported a response 
rate of 20% (3/15, 2 of the responders had mutant EGFR)233; a reduction in circulating tumor cells was 
noted and correlated with reduction in tumor size234. In a Phase 2 study of pertuzumab plus erlotinib in 
relapsed patients with NSCLC, PET-CT imaging showed that the primary endpoint of response rate (RR) 
was met in 19.5% of all patients (n = 41) and in 8.7% of patients with wild-type EGFR NSCLC (n = 23); 
however, 68.3% (28/41) of patients showed treatment-related grade 3 (or higher) adverse events235. 
Trastuzumab Approved Indications: Trastuzumab is a monoclonal antibody that targets the protein ERBB2/HER2. 
It is FDA approved for the treatment of breast cancers or metastatic gastric or gastroesophageal 
adenocarcinomas that overexpress HER2. 
Gene Association: ERBB2 amplification or activating mutations may confer sensitivity to 
trastuzumab. Trastuzumab-involving regimens elicited significant responses in patients with NSCLC 
and ERBB2 exon 20 insertions (8 partial responses (PRs) and 4 stable disease vs. 1 progressive 
disease) and in a patient with breast cancer harboring ERBB2 V777L and S310F activating 
mutations11,18. A patient with HER2-positive parotid salivary duct carcinoma also reported a PR 
following treatment with trastuzumab in combination with carboplatin and docetaxel236. 
Supporting Data: A Phase 2 clinical trial of docetaxel with trastuzumab in non-small cell lung cancer 
(NSCLC) reported partial responses in 8% of patients; response did not correlate with HER2 status as 
assessed by immunohistochemistry237. Another Phase 2 study of 169 patients with NSCLC reported an 
objective response rate of 23% (7/30 patients) in the patients treated with a combination therapy of 
docetaxel and trastuzumab, and 32% (11/34) in patients treated with paclitaxel and trastuzumab238. 
HER2 expression did not impact the results of this study238. A patient with lung adenocarcinoma that 
was HER-positive by FISH and harbored an ERBB2 G776L mutation experienced a partial response on 
trastuzumab and paclitaxel9. In a retrospective analysis of patients with NSCLC harboring ERBB2 exon 
20 insertion mutations, disease control was reported in 93% of patients (13/14) treated with 
trastuzumab in combination with chemotherapy11. 
Atezolizumab Approved Indications: Atezolizumab is a monoclonal antibody that binds to PD-L1 and blocks its 
interaction with PD-1 in order to enhance antitumor immune responses. It is FDA approved to treat 
patients with advanced urothelial carcinoma who progress during or following platinum-based 
chemotherapy. 
Gene Association: On the basis of emerging clinical data in patients with urothelial carcinoma45, non- 
small cell lung cancer (Spigel et al., 2016; ASCO Abstract 9017), or melanoma (Johnson et al., 2016; 
ASCO Abstract 105), high tumor mutation burden (TMB) may predict sensitivity to anti-PD-L1 therapies 
such as atezolizumab. S
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Supporting Data: A Phase 2 study of atezolizumab for the treatment of non-small cell lung carcinoma 
(NSCLC) reported significantly improved median overall survival (OS; 12.6 vs. 9.7 months) and 
objective response duration (18.6 vs. 7.2 months) when compared with docetaxel; PD-L1 expression 
correlated with improved response to atezolizumab (median OS 15.1 vs. 9.7 months) (Smith et al., 
2016; ASCO Abstract 9028)239. Patients on this study who continued on atezolizumab after 
experiencing progressive disease (PD) achieved responses in 11% of cases and a median OS of 11.1 
months, compared with 8.3 months for patients switching to different treatment (Mazieres et al., 
2016; ASCO Abstract 9032). In another study of atezolizumab in patients with NSCLC, an overall 
response rate (ORR) of 23% (12/53) and a median progression-free survival of 15 weeks were 
reported240. Atezolizumab achieved similar ORRs for patients with NSCLC who received no prior 
chemotherapy (19-29%), progressed on previous platinum therapy (17-27%), or had brain metastases 
or treated asymptomatic brain metastases (17%) (Besse et al., 2015; ECC Abstract 16LBA, Spigel et al., 
2015; ASCO Abstract 8028). 
Everolimus Approved Indications: Everolimus is an orally available mTOR inhibitor that is FDA approved to treat 
renal cell carcinoma (RCC) following antiangiogenic therapy; pancreatic neuroendocrine tumors and 
well-differentiated non-functional neuroendocrine tumors of the lung or gastrointestinal tract; and, in 
association with tuberous sclerosis complex (TSC), renal angiomyolipoma and subependymal giant cell 
astrocytoma. Everolimus is also approved to treat hormone receptor-positive, HER2-negative 
advanced breast cancer in combination with exemestane following prior therapy with letrozole or 
anastrozole, as well as in combination with the multikinase inhibitor lenvatinib to treat advanced 
RCC following prior antiangiogenic therapy. 
Gene Association: Preclinical data suggests that loss or inactivation of NF2 may be associated with 
sensitivity to rapamycin, which is similar in mechanism of action to everolimus74,75. Several case 
reports describe durable complete or partial responses of patients with NF2-mutant solid tumors to 
therapy regimens including everolimus or temsirolimus70,71,72,73. Increased mTOR signaling is present in 
LKB1-deficient tumors84,102,108,110,241; therefore, therapies targeting mTOR may be relevant for tumors 
with STK11 alterations84. Clinical responses to everolimus have been reported in patients with 
pancreatic cancer and STK11 alterations, with two patients exhibiting a partial response for more than 
6 months (Moreira et al. 2015; ASCO Abstract 315)115. 
Supporting Data: A trial of everolimus as a monotherapy in non-small cell lung cancer (NSCLC) showed 
modest activity242, but a Phase 2 study of everolimus in combination with docetaxel did not show any 
added benefit of everolimus in an unselected population (Khuri et al., 2011; ASCO Abstract e13601). A 
Phase 1 study evaluated the addition of everolimus to carboplatin and paclitaxel +/- bevacizumab in 
advanced NSCLC and found the combinations produced 1 complete response and 10 partial responses 
(n=52), although treatments were not well tolerated243. A Phase 1 study in patients with advanced 
NSCLC of the combination of everolimus and erlotinib reported 9 objective responses and 28 patients 
experiencing stable disease (n=74), but a Phase 2 study found the combination inefficacious at 
tolerated doses244,245. A trial of combination treatment with sorafenib and everolimus that included 2 
patients with lung adenocarcinoma reported a partial response in one patient and stable disease in 
the other, with both patients experiencing progression-free survival of more than 4 
months246. A Phase 1b trial of a combination of everolimus and the MEK inhibitor trametinib in patients 
with solid tumors reported frequent adverse events and the study was unable to identify a 
recommended Phase 2 dose and schedule for the combination83. 
Temsirolimus Approved Indications: Temsirolimus is an intravenous mTOR inhibitor that is FDA approved to treat 
advanced renal cell carcinoma. 
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Gene Association: Preclinical data suggests that loss or inactivation of NF2 may be associated with 
sensitivity to rapamycin, which has a similar mechanism of action to temsirolimus74,75. Several case 
reports describe durable complete or partial responses of patients with NF2-mutant solid tumors to 
therapy regimens including everolimus or temsirolimus70,71,72,73. Increased mTOR signaling is present in 
LKB1-deficient tumors84,102,108,110,241; therefore, therapies targeting mTOR may be relevant for tumors 
with STK11 alterations84. 
Supporting Data: In a Phase 2 clinical trial in NSCLC, front-line temsirolimus monotherapy 
demonstrated some clinical benefit but failed to meet the trial's primary end point247. In a Phase 1 
trial of temsirolimus and radiation in patients with NSCLC, of 8 evaluable patients, 3 exhibited a partial 
response, and 2 exhibited stable disease248. 
Genomic alterations detected may be associated with activity of certain approved drugs; however, the agents listed in this report may have little or 
no evidence in the patient’s tumor type. 
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CLINICAL TRIALS TO CONSIDER 
IMPORTANT: While every effort is made to ensure the accuracy of the information contained below, the information available in the public 
domain is continually updated and should be investigated by the physician or research staff. This is not meant to be a complete list of available 
trials. In order to conduct a more thorough search, please go to www.clinicaltrials.gov and use the search terms provided below. For more 
information about a specific clinical trial, type the NCT ID of the trial indicated below into the search bar. 
GENE RATIONALE FOR POTENTIAL CLINICAL TRIALS 
ERBB2 amplification or activating mutations may confer sensitivity to HER2-targeted and dual 
EGFR/HER2-directed therapies, and may enhance efficacy of chemotherapy or other targeted therapies, 
ERBB2 
amplification - 
equivocal 
such as HSP90 inhibitors. 
Examples of clinical trials that may be appropriate for this patient are listed below. These trials were 
identified through a search of the trial website clinicaltrials.gov using keyword terms such as "ERBB2", 
"HER2", "trastuzumab", "lapatinib", "pertuzumab", "ado-trastuzumab emtansine", "afatinib", "HSP90", 
"NSCLC", "lung", "solid tumor", and/or "advanced cancer". 
TITLE PHASE TARGETS LOCATIONS NCT ID 
Phase I Active Immunotherapy Trial With a 
Combination of Two Chimeric (Trastuzumab- 
like and Pertuzumab-like)Human Epidermal 
Growth Factor Receptor 2 (HER-2) B Cell 
Peptide Vaccine Emulsified in ISA 720 and Nor- 
MDP Adjuvant in Patients With Advanced Solid 
Tumors 
Phase 1 ERBB2 Ohio NCT01376505 
An Open-label, Multicenter, Multinational, 
Phase 2 Study Exploring the Efficacy and Safety 
of Neratinib Therapy in Patients With Solid 
Tumors With Activating HER2, HER3 or EGFR 
Mutations or With EGFR Gene Amplification. 
Phase 2 EGFR, ERBB2, 
ERBB4 
California, Florida, 
Massachusetts, Missouri, New 
Jersey, New York, Tennessee, 
Texas, Barcelona (Spain), 
Cremona (Italy), Helsinki 
(Finland), London (United 
Kingdom), Madrid (Spain), 
Petch Tiqwa (Israel), Rehovot 
(Israel), Seoul (Korea, Republic 
of), Torino (Italy), Valencia 
(Spain), Victoria (Australia) 
NCT01953926 
Targeted Agent and Profiling Utilization 
Registry (TAPUR) Study 
Phase 2 ALK, Others Michigan, North Carolina NCT02693535 
My Pathway: An Open Label Phase IIa Study 
Evaluating Trastuzumab/Pertuzumab, Erlotinib, 
Vemurafenib, and Vismodegib in Patients Who 
Have Advanced Solid Tumors With Mutations 
or Gene Expression Abnormalities Predictive of 
Response to One of These Agents 
Phase 2 EGFR, ERBB2, 
BRAF, SMO 
Arizona, Arkansas, California, 
Colorado, Florida, Georgia, 
Illinois, Maryland, Minnesota, 
New York, North Carolina, 
North Dakota, Ohio, 
Oklahoma, Oregon, 
Pennsylvania, South Dakota, 
Tennessee, Texas, Virginia, 
Washington 
NCT02091141 
Phase I Trial Evaluating Safety and Tolerability 
of the Irreversible Epidermal Growth Factor 
Receptor Inhibitor Afatinib (BIBW 2992) in 
Phase 1 EGFR, ERBB2, 
KIT, PDGFRs, 
SRC, ABL 
Florida NCT01999985 SA
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Combination With the SRC Kinase Inhibitor 
Dasatinib for Patients With Non-small Cell Lung 
Cancer (NSCLC) 
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CLINICAL TRIALS TO CONSIDER 
GENE RATIONALE FOR POTENTIAL CLINICAL TRIALS 
High tumor mutational burden may predict response to anti-PD-1 and anti-PD-L1 immune checkpoint 
Tumor Mutation 
Burden 
TMB-High; 37.53 
Muts/Mb 
inhibitors. 
Examples of clinical trials that may be appropriate for this patient are listed below. These trials were 
identified through a search of the trial website clinicaltrials.gov using keyword terms such as "PD-L1", 
"B7-H1", "PD-1", "pembrolizumab", "nivolumab", "atezolizumab", "MPDL3280A", "durvalumab", 
"MEDI4736", "avelumab", "MSB0010718C", "BMS-936559", "CT-011", "NSCLC", "lung", "solid tumor", 
and/or "advanced cancer". 
TITLE PHASE TARGETS LOCATIONS NCT ID 
A Phase Ib Study of the Safety and 
Pharmacology of Atezolizumab (Anti-PD-L1 
Antibody) Administered With Bevacizumab 
and/or With Chemotherapy in Patients With 
Advanced Solid Tumors 
Phase 1 PD-1, VEGFA Colorado, Connecticut, District 
of Columbia, Illinois, 
Massachusetts, New York, 
North Carolina, Tennessee 
NCT01633970 
A Phase II Trial of Concurrent Chemoradiation 
With Consolidation Pembrolizumab (MK-3475) 
for the Treatment of Inoperable or 
Unresectable Stage III Non-Small Cell Lung 
Cancer (NSCLC): HCRN LUN14-179 
Phase 2 PD-1 California, Indiana, Nebraska, 
New Jersey 
NCT02343952 
A Phase III, Open-Label, Randomized Study of 
Atezolizumab (MPDL3280A, Anti-Pd-L1 
Antibody) in Combination With Carboplatin or 
Cisplatin + Pemetrexed Compared With 
Carboplatin or Cisplatin + Pemetrexed in 
Patients Who Are Chemotherapy-Naive and 
Have Stage IV Non-Squamous Non-Small Cell 
Lung Cancer 
Phase 3 PD-L1 California, Connecticut, Florida, 
Georgia, Illinois, Indiana, 
Kentucky, Michigan, Nebraska, 
Oregon, Pennsylvania, Texas, 
Virginia, Washington, 
Wisconsin, Aichi (Japan), 
Alicante (Spain), Barcelona 
(Spain), Bunkyo-ku (Japan), 
Burgos (Spain), Creteil 
(France), Guipuzcoa (Spain), 
Hiroshima (Japan), Hokkaido 
(Japan), Hyogo (Japan), 
Ishikawa (Japan), Kagoshima 
(Japan), Kanagawa (Japan), La 
Coruña (Spain), Limoges 
(France), Malaga (Spain), 
Michalovce (Slovakia), Navarra 
(Spain), Niigata (Japan), Osaka 
(Japan), Piemonte (Italy), Saga 
(Japan), Tokyo (Japan), 
Yamaguchi (Japan) 
NCT02657434 
A Randomized, Double-Blind, Phase III Study of 
Carboplatin-Paclitaxel/Nab-Paclitaxel 
Chemotherapy With or Without 
Pembrolizumab (MK-3475) in First Line 
Metastatic Squamous Non-small Cell Lung 
Cancer Subjects (KEYNOTE-407) 
Phase 3 PD-1 California, Illinois, Maryland, 
Massachusetts, New York, 
North Carolina, South Carolina, 
Moscow (Russian Federation), 
North Ryde (Australia) 
NCT02775435 SA
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An Open-Label, Randomized Phase 3 Trial of 
Nivolumab, or Nivolumab Plus Ipilimumab, or 
Nivolumab Plus Platinum Doublet 
Chemotherapy Versus Platinum Doublet 
Chemotherapy in Subjects With Chemotherapy- 
Naïve Stage IV or Recurrent Non-Small Cell 
Lung Cancer (NSCLC) 
Phase 3 PD-1, CTLA4 Alabama, California, 
Connecticut, Georgia, 
Kentucky, Maryland, Missouri, 
New Jersey, New York, North 
Carolina, Ohio, Pennsylvania, 
South Carolina, Tennessee, 
Texas, Utah, Washington, 
multiple ex-US locations 
NCT02477826 
A Dose Frequency Optimization, Phase IIIB/IV 
Trial of Nivolumab 240 mg Every 2 Weeks vs 
Nivolumab 480 mg Every 4 Weeks in Subjects 
With Advanced or Metastatic Non-small Cell 
Lung Cancer Who Received 4 Months of 
Nivolumab at 3 mg/kg or 240 mg Every 2 
Weeks 
Phase 3 PD-1 Arizona, California, Colorado, 
Florida, Illinois, Maryland, 
Nebraska, New York, Ohio, 
Oregon, South Carolina, 
Tennessee, Texas, Virginia, 
Washington, Ontario (Canada) 
NCT02713867 
A Phase III, Open-Label, Multicenter, 
Randomized Study to Investigate the Efficacy 
and Safety of Atezolizumab (Anti-PD-L1 
Antibody) Compared With Docetaxel in Patients 
With Non-Small Cell Lung Cancer After Failure 
With Platinum-Containing Chemotherapy 
[IMpower210] 
Phase 3 PD-L1 Changchun (China), Daegu 
(Korea, Republic of), 
Daejeon (Korea, Republic 
of), Guangzhou (China), 
Hangzhou (China), 
Jeollanam-do (Korea, 
Republic of), Seoul 
(Korea, Republic of), 
Shanghai (China), Tianjin 
(天津) (China) 
NCT02813785 
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CLINICAL TRIALS TO CONSIDER 
GENE RATIONALE FOR POTENTIAL CLINICAL TRIALS 
NF2 
E427* 
Inactivation or loss of NF2 results in the dysregulation of mTOR and FAK pathway signaling. Therefore, 
mTOR and/or FAK inhibitors may be relevant for patients with NF2 inactivating mutations. 
Examples of clinical trials that may be appropriate for this patient are listed below. These trials were 
identified through a search of the trial website clinicaltrials.gov using keyword terms such as "NF2", 
"mTOR", "FAK", "everolimus", "temsirolimus", "GSK2256098", "VS-4718", "defactinib", "NSCLC", "lung", 
"solid tumor" and/or "advanced cancer". 
TITLE PHASE TARGETS LOCATIONS NCT ID 
A Phase I Study of BKM120 and Everolimus in 
Advanced Solid Malignancies 
Phase 1 PI3K, mTOR Georgia NCT01470209 
A Phase I Study of VS-4718, a Focal Adhesion 
Kinase Inhibitor, in Subjects With Metastatic 
Non-Hematologic Malignancies 
Phase 1 FAK Arizona, California, Florida, 
Tennessee 
NCT01849744 
A Phase Ib/IIa Study of AZD2014 in 
Combination With Selumetinib in Patients With 
Advanced Cancers 
Phase 
1/Phase 
2 
mTORC1, 
mTORC2, MEK 
London (United Kingdom) NCT02583542 
Phase II Study of Everolimus in Patients With 
Advanced Solid Malignancies With TSC1 and 
TSC2 Mutations 
Phase 2 mTOR Missouri NCT02352844 
A Multicenter, Open-label, Phase 1b Study of 
MLN0128 (an Oral mTORC1/2 Inhibitor) in 
Combination With MLN1117 (an Oral PI3Kα 
Inhibitor) in Adult Patients With Advanced 
Nonhematologic Malignancies 
Phase 1 PI3K-alpha, 
mTORC1, 
mTORC2 
Massachusetts, Tennessee, 
Texas, Barcelona (Spain), 
Sutton (United Kingdom) 
NCT01899053 
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CLINICAL TRIALS TO CONSIDER 
GENE RATIONALE FOR POTENTIAL CLINICAL TRIALS 
STK11 
splice site 921-1G>C 
STK11 loss or inactivating mutations may predict sensitivity to mTOR inhibitors or SRC inhibitors. 
Examples of clinical trials that may be appropriate for this patient are listed below. These trials were 
identified through a search of the trial website clinicaltrials.gov using keyword terms such as "mTOR", 
"SRC", "everolimus", "temsirolimus", "dasatinib", "bosutinib", "NSCLC", "lung", "solid tumor", and/or 
"advanced cancer". 
TITLE PHASE TARGETS LOCATIONS NCT ID 
A Phase I Study of BKM120 and Everolimus in 
Advanced Solid Malignancies 
Phase 1 PI3K, mTOR Georgia NCT01470209 
A Multicenter, Open-label, Phase 1b Study of 
MLN0128 (an Oral mTORC1/2 Inhibitor) in 
Combination With MLN1117 (an Oral PI3Kα 
Inhibitor) in Adult Patients With Advanced 
Nonhematologic Malignancies 
Phase 1 PI3K-alpha, 
mTORC1, 
mTORC2 
Massachusetts, Tennessee, 
Texas, Barcelona (Spain), 
Sutton (United Kingdom) 
NCT01899053 
Phase I Trial Evaluating Safety and Tolerability 
of the Irreversible Epidermal Growth Factor 
Receptor Inhibitor Afatinib (BIBW 2992) in 
Combination With the SRC Kinase Inhibitor 
Dasatinib for Patients With Non-small Cell Lung 
Cancer (NSCLC) 
Phase 1 EGFR, ERBB2, 
KIT, PDGFRs, 
SRC, ABL 
Florida NCT01999985 
Phase I Study of MLN0128 (NSC# 768435) in 
Combination With Ziv-Aflibercept (NSC# 
724770) in Patients With Advanced Cancers 
Phase 1 mTORC1, 
mTORC2 
Texas NCT02159989 
A Phase 1, Open-label Study to Evaluate the 
Safety, Tolerability, and Pharmacokinetics of 
MLN0128 (an Oral mTORC 1/2 Inhibitor) as a 
Single Agent and in Combination With 
Paclitaxel in Adult Patients With Advanced 
Nonhematologic Malignancies 
Phase 1 mTORC1, 
mTORC2 
Florida, Oklahoma, Tennessee NCT02412722 
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APPENDIX 
VARIANTS OF UNKNOWN SIGNIFICANCE 
Note: One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been 
adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these 
alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in 
the future. 
AKT3 ARAF BTK CD79B CDK12 CDK8 
E115K G446D E215V splice site 592- amplification M273I 
CSF1R 
L471M 
GPR124 
Q227K,V688L 
Microsatellite 
status 
MS-Stable 
PRDM1 
amplification 
WISP3 
amplification 
EPHA5 
N120K 
HSD3B1 
V224_V226>G*CV, 
Y225C 
MLL2 
Q3738H 
PRKDC 
E2175Q,rearrange 
ment 
ERBB4 
N1029K,splice site 
3136-2A>T 
IL7R 
H309Q 
MLL3 
C388F 
RUNX1T1 
D477Y,V16L 
2A>C 
FLT4 
E1002K 
KEAP1 
E488K 
NOTCH1 
G661S 
SLIT2 
V1290A 
GLI1 
R1068G 
LRP1B 
D3844H,G4366W 
NTRK3 
H632N 
SMO 
V294F 
GNAS 
P98L 
MDM2 
G137C 
PIK3CG 
L838M 
SPOP 
amplification 
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APPENDIX 
GENES ASSAYED IN FOUNDATIONONE 
FoundationOne is designed to include all genes known to be somatically altered in human solid tumors that are validated targets for 
therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The 
current assay interrogates 315 genes as well as introns of 28 genes involved in rearrangements. The assay will be updated periodically 
to reflect new knowledge about cancer biology. 
DNA Gene List: Entire Coding Sequence for the Detection of Base Substitutions, Insertion/Deletions, and Copy Number Alterations 
ABL1 
ARAF
ABL2 
ARFRP1
ACVR1B 
ARID1A
AKT1 
ARID1B
AKT2 
ARID2
AKT3 
ASXL1
ALK 
ATM
AMER1 
(FAM123B) 
ATR
APC 
ATRX
AR 
AURKA
AURKB AXIN1 AXL BAP1 BARD1 BCL2 BCL2L1 BCL2L2 BCL6 BCOR
BCORL1 BLM BRAF BRCA1 BRCA2 BRD4 BRIP1 BTG1 BTK C11orf30 (EMSY)
CARD11 CBFB CBL CCND1 CCND2 CCND3 CCNE1 CD274 CD79A CD79B
CDC73 CDH1 CDK12 CDK4 CDK6 CDK8 CDKN1A CDKN1B CDKN2A CDKN2B
CDKN2C CEBPA CHD2 CHD4 CHEK1 CHEK2 CIC CREBBP CRKL CRLF2
CSF1R CTCF CTNNA1 CTNNB1 CUL3 CYLD DAXX DDR2 DICER1 DNMT3A
DOT1L EGFR EP300 EPHA3 EPHA5 EPHA7 EPHB1 ERBB2 ERBB3 ERBB4
ERG ERRFI1 ESR1 EZH2 FAM46C FANCA FANCC FANCD2 FANCE FANCF
FANCG FANCL FAS FAT1 FBXW7 FGF10 FGF14 FGF19 FGF23 FGF3
FGF4 FGF6 FGFR1 FGFR2 FGFR3 FGFR4 FH FLCN FLT1 FLT3
FLT4 FOXL2 FOXP1 FRS2 FUBP1 GABRA6 GATA1 GATA2 GATA3 GATA4
GATA6 GID4 (C17orf39) GLI1 GNA11 GNA13 GNAQ GNAS GPR124 GRIN2A GRM3
GSK3B H3F3A HGF HNF1A HRAS HSD3B1 HSP90AA1 IDH1 IDH2 IGF1R
IGF2 IKBKE IKZF1 IL7R INHBA INPP4B IRF2 IRF4 IRS2 JAK1
JAK2 JAK3 JUN KAT6A (MYST3) KDM5A KDM5C KDM6A KDR KEAP1 KEL
KIT KLHL6 KMT2A (MLL) KMT2C (MLL3) KMT2D (MLL2) KRAS LMO1 LRP1B LYN LZTR1
MAGI2 MAP2K1 MAP2K2 MAP2K4 MAP3K1 MCL1 MDM2 MDM4 MED12 MEF2B
MEN1 MET MITF MLH1 MPL MRE11A MSH2 MSH6 MTOR MUTYH
MYC MYCL (MYCL1) MYCN MYD88 NF1 NF2 NFE2L2 NFKBIA NKX2-1 NOTCH1
NOTCH2 NOTCH3 NPM1 NRAS NSD1 NTRK1 NTRK2 NTRK3 NUP93 PAK3
PALB2 PARK2 PAX5 PBRM1 PDCD1LG2 PDGFRA PDGFRB PDK1 PIK3C2B PIK3CA
PIK3CB PIK3CG PIK3R1 PIK3R2 PLCG2 PMS2 POLD1 POLE PPP2R1A PRDM1
PREX2 PRKAR1A PRKCI PRKDC PRSS8 PTCH1 PTEN PTPN11 QKI RAC1
RAD50 RAD51 RAF1 RANBP2 RARA RB1 RBM10 RET RICTOR RNF43
ROS1 RPTOR RUNX1 RUNX1T1 SDHA SDHB SDHC SDHD SETD2 SF3B1
SLIT2 SMAD2 SMAD3 SMAD4 SMARCA4 SMARCB1 SMO SNCAIP SOCS1 SOX10
SOX2 SOX9 SPEN SPOP SPTA1 SRC STAG2 STAT3 STAT4 STK11
SUFU SYK TAF1 TBX3 TERC
TERT 
(promoter only ) TET2 TGFBR2 TNFAIP3 TNFRSF14
TOP1 TOP2A TP53 TSC1 TSC2 TSHR U2AF1 VEGFA VHL WISP3
WT1 XPO1 ZBTB2 ZNF217 ZNF703
DNA Gene List: For the Detection of Select Rearrangements 
ALK BCL2 BCR BRAF BRCA1 BRCA2 BRD4 EGFR ETV1 ETV4
ETV5 ETV6 FGFR1 FGFR2 FGFR3 KIT MSH2 MYB MYC NOTCH2
NTRK1 NTRK2 PDGFRA RAF1 RARA RET ROS1 TMPRSS2
Additional Assays: For the Detection of Select Cancer Biomarkers 
Microsatellite status 
Tumor Mutation Burden 
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APPENDIX 
FOUNDATIONONE PERFORMANCE SPECIFICATIONS 
ACCURACY
Sensitivity: Base Substitutions
At Mutant Allele Frequency ≥10% >99.9%  (CI* 99.6%-100%)
At Mutant Allele Frequency 5-10% 99.3%  (CI* 98.3%-99.8%)
Sensitivity: Insertions/Deletions (1-40 bp)
At Mutant Allele Frequency ≥20% 97.9%  (CI* 92.5%-99.7%)
At Mutant Allele Frequency 10-20% 97.3%  (CI* 90.5%-99.7%)
Sensitivity: Copy Number Alterations—Amplifications 
(ploidy <4, Amplification with Copy Number ≥8)
At ≥30% tumor nuclei >99.0%  (CI* 93.6%-100%)
At  20% tumor nuclei 92.6%  (CI* 66.1%-99.8%)
Sensitivity: Copy Number Alterations—Deletions 
(ploidy <4, Homozygous Deletions)
At ≥30% tumor nuclei 97.2%  (CI* 85.5%-99.9%)
At  20% tumor nuclei 88.9%  (CI* 51.8%-99.7%)
Sensitivity: Rearrangements (selected rearrangements in specimens with ≥20% tumor nuclei)**
>90.0% 1 
>99.0%  for ALK fusion2 
(CI* 89.1%-100%)
Sensitivity: Microsatellite status At ≥20% tumor nuclei 97.0%  (CI* 89.6%-99.6%)
Specificity: all variant types Positive Predictive Value (PPV) >99.0%
Specificity: Microsatellite status Positive Predictive Value (PPV) >95.0%
Accuracy: Tumor Mutation Burden At ≥20% tumor nuclei >90.0%
REPRODUCIBILITY (average concordance between replicates)
96.4% inter-batch precision
98.9% intra-batch precision
95.8% microsatellite status precision
96.4% tumor mutation burden precision
* 95% Confidence Interval
** Performance for gene fusions within targeted introns only. Sensitivity for gene fusions occurring outside targeted introns or in highly repetitive intronic sequence contexts is reduced. 
1 Based on analysis of coverage and rearrangement structure in the COSMIC database for the solid tumor fusion genes where alteration prevalence could be established, complemented 
by detection of exemplar rearrangements in cell line titration experiments. 
2 Based on ALK rearrangement concordance analysis vs. a standard clinical FISH assay described in: Yelensky, R. et al. Analytical validation of solid tumor fusion gene detection in a 
comprehensive NGS-based clinical cancer genomic test, In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. 
Philadelphia (PA): AACR; 2014. Abstract nr 4699 
Assay specifications were determined for typical median exon coverage of approximately 500X. For additional information regarding the validation of FoundationOne, please refer to 
the article, Frampton, GM. et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing, Nat Biotechnol (2013 Oct. 20). 
Microsatellite status (a measure of microsatellite instability, or “MSI”) is determined by assessing indel characteristics at 114 homopolymer repeat loci in or near the targeted gene 
regions of the FoundationOne test. Microsatellite status is assayed for all FoundationOne samples. MSI-High results are reported in all tumor types. In select tumor types, other 
Microsatellite status results may be reported (MS-Stable, MSI-Ambiguous, MSI-Unknown) when relevant. Microsatellite status result may be reported as "Unknown" if the sample is 
not of sufficient quality to confidently determine Microsatellite status. 
Tumor Mutation Burden (TMB) is determined by measuring the number of somatic mutations occurring in sequenced genes on the FoundationOne and FoundationOne Heme tests and 
extrapolating to the genome as a whole. TMB is assayed for all FoundationOne and FoundationOne Heme samples. TMB-High results are reported in all tumor types. In select tumor 
types, other TMB results may be reported (TMB-Intermediate, TMB-Low, TMB-Unknown) when relevant. TMB results are determined as follows: TMB-High corresponds to greater than 
or equal to 20 mutations per megabase (Muts/Mb); TMB-Intermediate corresponds to 6-19 Muts/Mb; TMB-Low corresponds to less than or equal to 5 Muts/Mb. Tumor Mutation 
Burden may be reported as "Unknown" if the sample is not of sufficient quality to confidently determine Tumor Mutation Burden. 
For additional information specific to the performance of this specimen, please contact Foundation Medicine, Inc. at 1-888-988-3639. SA
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ABOUT FOUNDATIONONE™ 
FoundationOne™: FoundationOne was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation 
Medicine). FoundationOne has  not  been  cleared or  approved by  the  United States Food  and  Drug  Administration (FDA). The  FDA  has 
determined that such clearance or approval is not necessary. FoundationOne may be used for clinical purposes and should not be regarded 
as purely investigational or for research only. Foundation Medicine’s clinical reference laboratory is certified under the Clinical Laboratory 
Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. 
Diagnostic Significance: FoundationOne identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some 
cases, the Test Report also highlights selected negative test results regarding biomarkers of clinical significance. 
Qualified Alteration Calls (Equivocal and Subclonal): An alteration denoted as “amplification – equivocal” implies that the FoundationOne 
assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number 
amplification. The threshold used in FoundationOne for identifying a copy number amplification is five (5) for ERBB2 and six (6) for all other 
genes.  Conversely,  an  alteration  denoted  as  “loss  –  equivocal”  implies  that  the  FoundationOne  assay  data  provide  some,  but  not 
unambiguous,  evidence  for  homozygous  deletion  of  the  gene  in  question.  An  alteration  denoted  as  “subclonal”  is  one  that  the 
FoundationOne analytical methodology has identified as being present in <10% of the assayed tumor DNA. 
The  Report incorporates analyses of  peer-reviewed studies and  other publicly available information identified by  Foundation Medicine; 
these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with 
potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. 
NOTE: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment 
regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug 
or treatment regimen. 
Alterations and Drugs Not Presented in Ranked Order: In this Report, neither any biomarker alteration, nor any drug associated with 
potential clinical benefit (or potential lack of clinical benefit), are ranked in order of potential or predicted efficacy. 
Level of Evidence Not Provided: Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or 
level of published evidence. 
No Guarantee of Clinical Benefit: This Report makes no promises or guarantees that a particular drug will be effective in the treatment of 
disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact 
provide no clinical benefit. 
No Guarantee of Reimbursement: Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third 
party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne. 
Treatment Decisions are Responsibility of Physician: Drugs referenced in this Report may not be suitable for a particular patient. The 
selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within 
the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant 
information regarding a particular patient, before the patient’s treating physician recommends a course of treatment. 
Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into 
consideration all applicable information concerning the patient’s condition, such as patient and family history, physical examinations, 
information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating 
physician’s decisions should not be based on a single test, such as this Test, or the information contained in this Report. 
Certain sample or variant characteristics may result in reduced sensitivity. These include: subclonal alterations in heterogeneous samples, low 
sample quality or with homozygous losses of <3 exons; and deletions and insertions >40bp, or in repetitive/high homology sequences. 
FoundationOne is performed using DNA derived from tumor, and as such germline events may not be reported.  The following targets typically 
have low coverage resulting in a reduction in sensitivity: SDHD exon 6 and TP53 exon 1. 
FoundationOne complies with all European Union (EU) requirements of the IVD Directive 98/79EC.  As such, the FoundationOne Assay 
has been registered for CE mark by our EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. S
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SUPPLEMENTARY FIGURE S2 
Therapies associated with potential benefit or lack of benefit, as indicated above, are based on biomarker results provided in this report and are based on published medical evidence. This
evidence may have been obtained from studies performed in the cancer type present in the tested patient’s sample or derived from another tumor type. The selection of any, all, or none
of the matched therapies resides solely with the discretion of the treating physician. Decisions on patient care and treatment must be based on the independent medical judgment of
the treating physician, taking into consideration all available information in addition to this report concerning the patient’s condition in accordance with the applicable standard of care.
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Name: Patient, Test
Date of Birth: XX-Mon-1932
Sex: Male
Case Number: TN14-111111
Diagnosis:  Adenocarcinoma, NOS
Primary Tumor Site: Lung, NOS
Specimen Site: Lung, NOS
Specimen ID: ABC-12345-YZ
Specimen Collected: XX-Mon-2014
Completion of Testing: XX-Mon-2014
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Bold Therapies = On NCCN Compendium® Therapies
THERAPIES WITH POTENTIAL BENEFIT (PAGE 4)
afatinib EGFR✮
docetaxel,
nab-paclitaxel,
paclitaxel
TLE3✮, PGP
erlotinib PTEN, PIK3CA,
KRAS, EGFR✮
gemcitabine RRM1✮
irinotecan TOPO1
pemetrexed TS✮
capecitabine,
fluorouracil
TS✮
dacarbazine,
temozolomide
MGMT✮
doxorubicin,
epirubicin,
liposomal-
doxorubicin
PGP, TOP2A
gefitinib PTEN, PIK3CA,
KRAS, EGFR✮
✮ Indicates Clinical Trial Opportunity  • 282 Chemotherapy Trials  • 102 Targeted Therapy Trials  (See Clinical Trials ConnectorTM on page 8 for details.)
THERAPIES WITH POTENTIAL LACK OF BENEFIT (PAGE 6)
ceritinib ALK
crizotinib ROS1, ALK
dabrafenib,
vemurafenib
BRAF cetuximab EGFR
THERAPIES WITH INDETERMINATE BENEFIT (PAGE 7)
trastuzumab✝
ado-trastuzumab emtansine (T-DM1)✝,
pertuzumab✝
everolimus, temsirolimus
imatinib
lapatinib✝
vandetanib
✝Association to Benefit was not indicated due to assay failure.
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Biomarker Results continued on the next page. >
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SUMMARY OF BIOMARKER RESULTS (SEE APPENDIX FOR FULL DETAILS)
Biomarker Method Result
ABL1 NGS Mutation Not Detected
AKT1 NGS Quantity Not Sufficient
ALK FISH Negative
ALK NGS Mutation Not Detected
Androgen Receptor IHC Negative
APC NGS Mutation Not Detected
ATM NGS Mutation Not Detected
BRAF NGS Mutation Not Detected
CDH1 NGS Mutation Not Detected
c-KIT NGS Mutation Not Detected
cMET CISH Test Not Performed
cMET NGS Mutation Not Detected
cMET IHC Negative
CSF1R NGS Mutation Not Detected
CTNNB1 NGS Mutation Not Detected
Mutated, Pathogenic
EGFR NGS
Exon 21 | L858R
EGFR IHC (H-Score) Negative
ER IHC Negative
ERBB4 NGS Mutation Not Detected
FBXW7 NGS Mutation Not Detected
FGFR1 NGS Mutation Not Detected
FGFR2 NGS Mutation Not Detected
FLT3 NGS Mutation Not Detected
GNA11 NGS Quantity Not Sufficient
GNAQ NGS Mutation Not Detected
GNAS NGS Mutation Not Detected
Her2/Neu CISH Test Not Performed
Her2/Neu IHC Negative
Her2/Neu (ERBB2) NGS Mutation Not Detected
HNF1A NGS Mutation Not Detected
HRAS NGS Quantity Not Sufficient
IDH1 NGS Mutation Not Detected
JAK2 NGS Mutation Not Detected
JAK3 NGS Mutation Not Detected
Biomarker Method Result
KDR (VEGFR2) NGS Mutation Not Detected
KRAS NGS Mutation Not Detected
MGMT IHC Negative
MPL NGS Mutation Not Detected
NOTCH1 NGS Mutation Not Detected
NPM1 NGS Mutation Not Detected
NRAS NGS Mutation Not Detected
PD-1 IHC Negative
PDGFRA NGS Mutation Not Detected
PD-L1 IHC Negative
PGP IHC Negative
PIK3CA NGS Mutation Not Detected
PR IHC Negative
PTEN NGS Mutation Not Detected
PTEN IHC Positive
PTPN11 NGS Mutation Not Detected
RB1 NGS Mutation Not Detected
RET NGS Mutation Not Detected
ROS1 FISH Negative
RRM1 IHC Negative
SMAD4 NGS Mutation Not Detected
SMARCB1 NGS Mutation Not Detected
SMO NGS Quantity Not Sufficient
SPARC Monoclonal IHC Negative
SPARC Polyclonal IHC Positive
STK11 NGS Quantity Not Sufficient
TLE3 IHC Positive
TOP2A IHC Positive
TOPO1 IHC Positive
Mutated, Presumed
PathogenicTP53 NGS
Exon 5 | V173L
TS IHC Negative
TUBB3 IHC Positive
VHL NGS Quantity Not Sufficient
FISH: Fluorescence in situ hybridization IHC: Immunohistochemistry CISH: Chromogenic in situ hybridization NGS: Next-Generation Sequencing
SA
MP
LE
 R
EP
OR
T. 
 FO
R 
ILL
US
TR
AT
IV
E 
PU
RP
OS
ES
 O
NL
Y.
  N
OT
 FO
R 
CL
IN
IC
AL
 U
SE
.
PATIENT: Patient, Test (XX-Mon-1932) TN14-111111
4610 South 44th Place, Suite 100 • Phoenix, AZ 85040 • (888) 979-8669 • Fax: (866) 479-4925
CLIA 03D1019490 • CAP 7195577 • ISO 15189:2012 - 3531.01 • Zoran Gatalica, MD, DSc, Medical Director • ©2015 Caris Life Sciences. All rights reserved. Page 3 of 13
SUMMARY OF BIOMARKER RESULTS (SEE APPENDIX FOR FULL DETAILS)
The Next-Generation Sequencing results above include only the genes most commonly associated with cancer. See summary below and for
full Next-Generation Sequencing results, see Appendix page 1.
Genes tested: 44 | Genes with actionable mutations: 2 | Genes with unclassified mutations: 0 | Genes with no mutations detected: 36
See the Appendix section for a detailed overview of the biomarker test results for each technology.
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Additional Therapies Associated with Potential Benefit continued on the next page. >
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Clinical Association
Therapies Test Method Result Value✝ Potential
Benefit
Decreased
Potential
Benefit
Lack of
Potential
Benefit
Highest
Level of
Evidence*
Reference
afatinib EGFR
Next
Gen SEQ
Mutated,
Pathogenic
L858R ✔ I / Good 4#
capecitabine,
fluorouracil,
pemetrexed
TS IHC Negative 1+ 1% ✔ II-1 / Good 5#, 6#, 7
dacarbazine,
temozolomide
MGMT IHC Negative 1+ 10% ✔ II-2 / Good 19, 20
PGP IHC Negative 0+ 100% ✔ II-3 / Fair 22, 23#
TLE3 IHC Positive 2+ 30% ✔ II-2 / Good 21docetaxel, nab-
paclitaxel, paclitaxel
TUBB3 IHC Positive 3+ 90% ✔ I / Good
24, 25#,
26#, 27#
Her2/Neu CISH
Technical
Issues
PGP IHC Negative 0+ 100% ✔ II-1 / Fair 28, 29
doxorubicin,
epirubicin,
liposomal-
doxorubicin
TOP2A IHC Positive 2+ 10% ✔ I / Good 30, 31
cMET CISH
Technical
Issues
EGFR
Next
Gen SEQ
Mutated,
Pathogenic
L858R ✔ I / Good
35#, 37#,
38#, 39#
KRAS
Next
Gen SEQ
Mutation Not
Detected ✔ I / Good 35
#, 36#
PIK3CA
Next
Gen SEQ
Mutation Not
Detected ✔ II-1 / Good 33
#, 34#
erlotinib, gefitinib
PTEN IHC Positive 2+ 95% ✔ II-3 / Fair 32#
gemcitabine RRM1 IHC Negative 2+ 15% ✔ I / Good 43#
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Clinical Association
Therapies Test Method Result Value✝ Potential
Benefit
Decreased
Potential
Benefit
Lack of
Potential
Benefit
Highest
Level of
Evidence*
Reference
irinotecan TOPO1 IHC Positive 2+ 80% ✔ II-1 / Good 49, 50, 51
* The level of evidence for all references is assigned according to the Literature Level of Evidence Framework consistent with the US Preventive Services Task Force
described further in the Appendix of this report. The data level of each biomarker-drug interaction is the highest level of evidence based on the body of evidence, overall
clinical utility, competing biomarker interactions and tumor type from which the evidence was gathered.
# Evidence reference includes data from the same lineage as the tested specimen.
✝Refer to Appendix for detailed Result and Value information for each biomarker, including appropriate cutoffs, unit of measure, etc.
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Clinical Association
Therapies Test Method Result Value✝ Potential
Benefit
Decreased
Potential
Benefit
Lack of
Potential
Benefit
Highest
Level of
Evidence*
Reference
ceritinib ALK FISH Negative ✔ II-1 / Good 8#
cetuximab EGFR
IHC H-
Score
Negative 180 ✔ I / Good 9#
ALK FISH Negative ✔ I / Good 13#, 14#
crizotinib
ROS1 FISH Negative ✔ III / Good 10#, 11#, 12#
dabrafenib,
vemurafenib
BRAF
Next
Gen SEQ
Mutation Not
Detected ✔ I / Good
15#, 16,
17#, 18
* The level of evidence for all references is assigned according to the Literature Level of Evidence Framework consistent with the US Preventive Services Task Force
described further in the Appendix of this report. The data level of each biomarker-drug interaction is the highest level of evidence based on the body of evidence, overall
clinical utility, competing biomarker interactions and tumor type from which the evidence was gathered.
# Evidence reference includes data from the same lineage as the tested specimen.
✝Refer to Appendix for detailed Result and Value information for each biomarker, including appropriate cutoffs, unit of measure, etc.
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Clinical Association
Therapies Test Method Result Value✝ Potential
Benefit
Decreased
Potential
Benefit
Lack of
Potential
Benefit
Highest
Level of
Evidence*
Reference
Her2/Neu CISH
Technical
Issuesado-trastuzumab
emtansine (T-
DM1), pertuzumab Her2/Neu IHC Negative 0+ 100% ✔ I / Good 1, 2, 3
everolimus,
temsirolimus
PIK3CA
Next
Gen SEQ
Mutation Not
Detected ✔ II-2 / Good 40, 41
#, 42
c-KIT
Next
Gen SEQ
Mutation Not
Detected ✔ II-2 / Good 44, 45
imatinib
PDGFRA
Next
Gen SEQ
Mutation Not
Detected ✔ II-3 / Good 46, 47, 48
Her2/Neu CISH
Technical
Issues
lapatinib
Her2/Neu IHC Negative 0+ 100% ✔ I / Good 52, 53, 54
Her2/Neu CISH
Technical
Issues
Her2/Neu IHC Negative 0+ 100% ✔ I / Good
57, 58,
59, 60
trastuzumab
Her2/Neu
(ERBB2)
Next
Gen SEQ
Mutation Not
Detected ✔ II-3 / Good 55
#, 56#
vandetanib RET
Next
Gen SEQ
Mutation Not
Detected
I / Good 61
* The level of evidence for all references is assigned according to the Literature Level of Evidence Framework consistent with the US Preventive Services Task Force
described further in the Appendix of this report. The data level of each biomarker-drug interaction is the highest level of evidence based on the body of evidence, overall
clinical utility, competing biomarker interactions and tumor type from which the evidence was gathered.
# Evidence reference includes data from the same lineage as the tested specimen.
✝Refer to Appendix for detailed Result and Value information for each biomarker, including appropriate cutoffs, unit of measure, etc.
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CLINICAL TRIALS CONNECTOR T M
For a complete list of open, enrolling clinical trials visit MI Portal to access the Clinical Trials Connector . This personalized, real-time 
web-based service provides additional clinical trial information and enhanced searching capabilities, including, but not limited to:
• Location: filter by geographic area
• Biomarker(s): identify specific biomarkers associated with open clinical trials to choose from
• Drug(s): search for specific therapies
• Trial Sponsor: locate trials based on the organization supporting the trial(s)
Visit www.CarisMolecularIntelligence.com to view all matched trials.
CHEMOTHERAPY CLINICAL TRIALS (282)
Drug Class Biomarker Method Investigational Agent(s)
Alkylating agents (7) MGMT IHC dacarbazine, temozolomide
Antifolates (64) TS IHC methotrexate, pemetrexed
Nanoparticle-bound agents
(23)
SPARC Polyclonal IHC nab-paclitaxel
Nucleoside analog (53) RRM1 IHC gemcitabine
Pyrimidine analog (17) TS IHC capecitabine, fluorouracil
Taxanes (118) TLE3 IHC docetaxel, paclitaxel
TARGETED THERAPY CLINICAL TRIALS (102)
Drug Class Biomarker Method Investigational Agent(s)
Cell cycle inhibitors (5) TP53 Next Gen SEQ MK-1775
EGFR TKIs (77) EGFR Next Gen SEQ CO-1686, erlotinib, gefitinib
Pan-HER inhibitors (20) EGFR Next Gen SEQ afatinib, dacomitinib, icotinib, neratinib
( ) = represents the total number of clinical trials identified by the Clinical Trials Connector for the provided drug class or table.
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SUPPLEMENTARY FIGURE S3 
Precision Oncology Reports Survey Results
Figure S3.1.
In the past 12 months, for what percentage of your patients did you 
order tumor genomic testing? (n = 26)
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Figure S3.2.
  
Figure S3.3.
Which of the following vendor genomic test reports have you used?    
(n = 29, multiple answers allowed)
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Figure S3.4.
What is the most important information you expect to find in a tumor 
profiling report? (n = 32, multiple answers allowed)
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Figure S3.5.
What is the most time-consuming component of interpreting a tumor 
profiling report in your experience? (n = 28, multiple answers 
allowed)
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Figure S3.6.
What parts are most troublesome reading in these reports? (n = 29, multiple 
answers allowed)
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Figure S3.7.
Which feature(s) of one vendor report makes it harder to interpret data compared 
to another vendor report? (n = 28, multiple answers allowed)
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Figure S3.8.
How would you improve the effectiveness of oncology reports? (n = 26, multiple 
answers allowed)
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Figure S3.9.
Report Type Preference (n = 32)
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SUPPLEMENTARY TABLE 1 
Precision Oncology Reports Survey
Question 1-a: In the past 12 months, for what percentage of your patients 
did you order tumor genomic testing? Please include tests performed as 
part of a clinical trial. Your best estimate is fine.
 ______ %
Question 1-b: In the past 12 months, have you reviewed the following 
genomics test reports for your patients? Please check all that apply.
MSSM NGS Hotspot Cancer 
Panel 
BRAF 
EGFR 
KRAS 
MGMT 
MSI 
EML4-ALK 
C-KIT 
BCR-ABL 
JAK2 
PML-RARA 
MPL 
FLT3 
BCL2-IGH 
IGH rearrangement 
TRG rearrangement 
Other (p lease speci fy) 
_____________________ 
Question 2: Which of the following vendor genomic test reports have you 
used? Please check all that apply.
FoundationOne 
Guardant360 
OncoVantage 
Caris Molecular Intelligence 
Pathway Genomics 
None 
Other (please specify) ________________ 
Question 3: What is the most important information you expect to find in a 
tumor profiling report? Please check all that apply.
Genetic alterations/biomarkers 
Therapies 
Clinical trials 
Toxicity 
Other (please specify) _________________ 
Question 4: What is the most time-consuming component of interpreting a 
tumor profiling report in your experience? Please check all that apply.
Actionable genetic alterations/biomarkers 
Therapies 
Clinical trials 
Toxicity 
Other (please specify) __________________ 
Question 5: What parts are most troublesome reading in these reports? 
Please check all that apply.
Ease of locating the actionable summary 
Details of the actionable summary 
Verbosity of the technical information 
Ease of locating critical information 
Navigating cross-references in different sections of the report 
Other (please specify) __________________ 
Question 6: Which feature(s) of one vendor report makes it harder to 
interpret data compared to another vendor report? Please check all that 
apply.
Less technical details 
More technical details 
Layout/presentation of information 
Symbols and/or colors used to present information 
Not applicable 
Other (please specify) _______________________________ 
Question 7: How would you improve the effectiveness of oncology reports? 
Please check all that apply.
Add visualizations to summarize various data 
Add interactivity to the reports for better navigation and filtering 
Standardize the design of reports across vendors 
I am satisfied with current reports, no changes are necessary 
What do you suggest? _______________________________ 
Question 8: Which report type would you prefer?
Static (printed) report 
Online (interactive) report 
Both static and online 
Question 9: How many years has it been since you graduated from medical 
school?
0 - 5 
6 - 10 
11 - 15 
16 - 20 
21 - 25 
26 - 30 
31 - 35 
36 - 40 
over 40 years 
Question 10: What is your gender?
Male 
Female 
Question 11: Are you a …
Surgical oncologist 
Medical oncologist 
Radiation oncologist 
Other (please specify) ________________________ 
Question 12: What is your clinical focus? Please check all that apply.
Blood cancer 
Breast cancer 
Cancer genetics and prevention 
Cutaneous cancer 
Gastrointestinal cancer 
Genitourinary cancer 
Gynecological cancer 
Head and neck cancer 
Hematology 
Melanoma 
Neuro-Oncology 
Sarcoma 
Thoracic cancer 
Other (please specify) _________________________ 
COMMENTS
____________________________________________________
____________________________________________________
____________________________________________________
____________________________________________________
____________________________________________________
____________________________________________________
